Neuroanatomy of the bipolar brain: from brain structure to treatment by Vecchio, Daniela
 
 
 
 
 
 
 
 
 
Dottorato di Ricerca in Neuroscienze del 
Comportamento XXXI Ciclo 
Curricula di Neuropsicologia e Neuroscienze 
Cognitive 
 
 
 
 
Neuroanatomy of The Bipolar Brain: 
From Brain Structure to Treatment 
 
 
 
 
Candidate 
Daniela Vecchio 
Number 1050862 
 
Coordinator Tutor 
Prof. Stefano Ferraina Prof. Cecilia Guariglia 
 
 
 
A.A. 2017-2018 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
3 
 
 
 
 
 
INDEX 
 
 
 
Acknowledgement 5 
About this work 7 
Introduction 11 
CHAPTER 1: Neuroimaging and mental disorders 
1.1 History of Neuroimaging 14 
1.2 Neuroimaging Modalities 18 
1.2.1 Functional Magnetic Resonance Imaging 19 
1.2.2 Structural Magnetic Resonance Imaging 21 
1.2.3 sMRI: sequences and terminology 23 
1.2.4 Diffusion Neuroimaging 24 
1.3 Neuroimaging in Psychiatry 29 
1.3.1 Neuroimaging in Bipolar Disorder 32 
CHAPTER 2: (Study 1) Gray and white matter 
trajectories in patients with bipolar disorder 
2.1 Introduction 38 
2.2 Methods and Materials 40 
2.3 Results 47 
2.4 Discussion 54 
2.5 Limitations 60 
CHAPTER 3: (Study 2) Association between Duration 
of Lithium Exposure and Hippocampus/Amygdala 
4 
 
Volumes in Type I Bipolar Disorder 
3.1 Introduction 63 
3.2 Methods and Materials 66 
3.3 Results 72 
3.4 Discussion 77 
3.5 Limitations 81 
CHAPTER 4: (Study 3) Lithium treatment impacts 
nucleus accumbens shape in bipolar disorder 
4.1 Introduction 83 
4.2 Methods and Materials 85 
4.3 Results 92 
4.4 Discussion 99 
4.5 Limitations 104 
CHAPTER 5: Conclusions 106 
References 108 
APPENDIX I 125 
APPENDIX II 127 
APPENDIX III 129 
5 
 
Acknowledgement 
 
 
 
The studies here presented were developed at the IRCCS 
Santa Lucia Foundation, Neuropsychiatry Laboratory. I would 
like to address my gratification to Dr. Gianfranco Spalletta that 
allowed me to do this experience and to Dr. Fabrizio Piras and 
Dr. Federica Piras for their constant support. They helped me to 
overcome the various obstacles encountered in these years, in a 
priceless way, offering me a very fertile soil to grow. I also 
thank Dr. Valentina Ciullo, Dr. Nerissa Banaj, Dr. Tommaso 
Gili and all members of Neuropsychiatry Laboratory as their 
kindly presence had surrounded my daily work activities, 
making it really special as learning and working moments. As a 
work team, all of them contributed to make my PhD course 
period really stimulant and enriching, both from the 
professional and personal points of view. My gratifications also 
come to Neuroimaging Laboratory at the IRCCS Santa Lucia 
Foundation, to all persons and researcher working there, as they 
endured my constant presence and supported me in all my 
working needs. 
A special thank is for both patients and healthy controls 
that I tested during this period, for their collaboration and 
availability to spend with me so much hours of their time. 
Finally, the most special thanks are for my loved ones. My 
partner Luca, because he has never been tired of supporting my 
efforts and for my parents and my family because I always felt 
6 
 
close to them, even despite the kilometers that separated us 
because of my work. 
7 
 
About this work 
 
 
 
Since the beginning of my PhD course, my efforts have 
been aimed to constantly improve my knowledge about 
neuroimaging techniques and methodologies. I further deepened 
a promising, challenging and intriguing way to in vivo 
investigate neuroanatomical cerebral correlates of behavioural 
diseases, applying these techniques to neuropsychiatric 
research. Neuroimaging studies are widely diffused in 
neuroscientific research, with the aim to improve diagnostic and 
prognostic processes, but also to better characterise patients' 
pharmacological and clinical aspects. However, despite the 
efforts made so far, unanimous consensus on the 
neuropathological substrates on many of the more disabling 
psychiatric conditions is still missing. 
In this thesis, I summarised results from researches done 
during my PhD course, organising them in a brief introduction 
and five chapters. Specifically, the first chapter of this work is 
dedicated to the progress made during the past years in 
neuroimaging technologies and techniques, with a focus on 
structural Magnetic Resonance Imaging techniques and their 
employment into the neuropsychiatric research. 
The following three chapters are dedicated to the three 
studies, all developed though a specific research topic and 
directed to the understanding of the neural basis of Bipolar 
Disorder and its clinical implications. 
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The first cross-sectional case-control study I presented in 
chapter two was aimed at understanding whether white matter 
and grey matter changes are present from the beginning of the 
illness and whether they continue to be present over the course 
of the disease, in a sample of 78 patients (BD) and 78 controls 
(HC). With respect to HC, the study found that patients with BD 
showed a reduced brain volume in areas comprising the 
posterior cingulate cortex bilaterally, the right thalamus, the 
bilateral cerebellum and the left posterior limb of the internal 
capsule. The fact that these areas were permanently reduced 
over the entire age range investigated, suggests that brain 
alterations are present from the very early phase of the disorder, 
and that they are not the results of a neurodegenerative process. 
The second and the third studies I presented in chapters 
three and four are characterized by a strong clinical relevance, 
since they assessed the effect of lithium treatment (the gold 
standard treatment for BD patients) on brain structure. 
Specifically, study 2 was aimed at investigating the effects of 
lithium-treatment duration on the volumes of limbic and 
subcortical structures by comparing the groups of patients, 
stratified according to lithium exposure, (15 patients with a 
lithium exposure of less than 24 months (short-exposure group 
[SE]), and 15 patients naïve to treatment with lithium (no- 
exposure group [NE]) and HC. No differences in limbic and 
subcortical gray matter volumes were found between LE and 
HC. Hippocampal and amygdalar volumes were larger 
bilaterally in both LE and HC when compared to NE. 
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Amygdalar volumes were larger bilaterally in SE when 
compared to NE but did not differ from LE. Hippocampal 
volumes were smaller bilaterally in SE when compared to LE 
and HC but did not differ from NE. The study supports the idea 
that the effect of lithium exposure on limbic and subcortical 
gray matter volumes appears to be time-dependent and 
relatively specific to the hippocampus and the amygdala, with 
short-term effects on the amygdala and long-term effects on 
both structures. 
For the third study, I employed a recent structural 
neuroimaging approach (i.e. shape analysis) which allows the 
quantification of advanced morphometric features of deep grey 
matter structures. In this study, I tested the hypothesis  that 
shape characteristics of deep grey matter structures in bipolar 
disorder are associated with the duration of lithium treatment, 
finally impacting clinical phenomenology. The sample was 
composed of BD naïve to lithium treatment (NoLi), BD with 
short-term lithium treatment (LiTD-), BD with long-term 
lithium treatment (LiTD+), and HC. Results revealed a 
significant bilateral extroflexction effect dependent to increased 
duration of lithium treatment on the core of BD accumbens 
surfaces, while a concomitant introflection effect was found on 
the shell of right accumbens. A further analysis between groups 
with different treatment duration, showed that NoLi e LiTD- 
groups had inward/outward deformations both on left core and 
on the right shell of the accumbens surfaces when compared to 
HC and LiTD+. Moreover, the deformation of L-Accu-Core 
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shape was significantly correlated with increased depression 
severity. 
Finally, a conclusive chapter summarizes results and 
implications of the presented works. 
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Introduction 
 
 
 
The desire to understand the human mind has been one 
of the main desires of philosophers throughout the ages. 
During the last century, questions about cognitive and 
emotional process as well as about their cerebral 
neuroanatomical correlates have lead physician, 
psychologists, computer scientists, physicist to converge in 
the current discipline that is cognitive neuroscience. 
Non-invasive imaging of the human brain has proven 
invaluable in this context. Indeed, neuroimaging 
technologies have enabled the investigation of normal brain 
functions and are being used to gain important new insights 
into the mechanisms behind many neuropsychiatric 
disorders. This research has implications in identifying 
biomarkers of disease, prognosis, treatment effects, 
elucidate biological pathways, and help redefine diagnostic 
boundaries and inform and monitor new therapies. 
Unlike many neurological diseases, psychiatric 
disorders do not cause changes that are visible to the naked 
eye in the neuroimaging study of the individual patient 
(Agarwal et al., 2010). They are, however, amenable to 
investigation by recent neuroimaging modalities, 
particularly quantitative structural imaging. This was the 
reason for the rapid growth of magnetic resonance imaging 
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(MRI) research of psychiatric disorders. It has reflected the 
aspirations of many psychiatrists and neuropsychologist to 
link the signs and symptoms of psychiatric disease to 
specific brain structural abnormalities. 
Bipolar disorder (BD) is an especially good example of 
a group of psychiatric illnesses that are difficult to diagnose 
accurately. Specifically, BD is a mental health condition 
defined by periods (better known as episodes) of extreme 
affective disturbances, marked by alternating status of mood 
elation (mania/hypomania) and depression interspersed by 
euthymic (normal mood) periods. There are two main types 
of bipolar disorders: bipolar type I and bipolar type II. 
According to the DSM 5 (American Psychiatric  
Association. DSM-5 Task Force., 2013), BD type I involves 
episodes of severe mania and often depression, while BD 
type II involves a less severe form of mania called 
hypomania and depressive episodes are more frequent than 
in type I. 
Although BD, along with other psychiatric illnesses, is 
one of the ten most debilitating of all non-communicable 
diseases (Department of Health Statistics and Informatics, 
2008), misdiagnosis of the illness as recurrent unipolar 
depression occurs in 60% of patients seeking treatment for 
depression (Goodwin and Jamison, 2012; Hirschfeld et al., 
2003). Structural neuroimaging data had provided evidence 
for the assumption that Bipolar disorder are not exclusively 
functional illnesses but also show a diversity of 
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morphological changes. They allow investigation on 
potential neurodevelopmental and neurodegenerative 
processes involved in the disease and in their specific time 
course. Indeed, the identification of objective neuroimaging 
biomarkers that represent pathophysiologic processes that 
differ between bipolar disorder and other psychiatric 
diseases can both inform bipolar disorder diagnosis and 
provide biological targets for the development of new and 
personalized treatments. This is mostly important at the 
presentation of first episodes of the disorder, when different 
diagnosis can show confounding symptomatology 
overlapping (Rosen et al., 2012). 
As the size of the experimental cohorts grew, studies 
began to examine brain patterns associated with 
heterogeneous expression of clinical symptoms, the 
mechanisms of disease progression, and even differential 
patterns of treatment response. 
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CHAPTER 1 
 
 
 
NEUROIMAGING 
 
 
 
1.1 History of Neuroimaging 
 
 
In the last twenty years, neuroimaging of the brain has 
advanced at a tremendous pace because of technological 
innovations, developments in computing and new statistics 
that have been developed to interrogate neuroimaging data. 
The history of modern in vivo imaging began from the 
side of the structural tissue visualization, with radiographic 
techniques. However, since the brain is composed of soft 
tissue, that is not radio-opaque, it remained essentially 
invisible to plain X-ray investigations. The first attempt to 
visualize the brain traces back to 1918, when the work of 
the neurosurgeon Walter Dandy (Kilgore and Elster, 1995) 
on experimental hydrocephalus and cerebrospinal fluid 
circulation led to the development of 
pneumoencephalography (Sampath et al., 2000). Most of 
cerebrospinal fluid was temporarily replaced trough a 
lumbar puncture with a contrast agent such as air, oxygen or 
helium, to improve brain contrast when imaging it with X- 
rays. It was derived from ventriculography, an earlier 
method where the air was injected through holes drilled in 
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the skull of the patient. Pneumoencephalography become a 
common medical procedure mostly used to evaluate the size 
of brain ventricles until the late 1970s. In 1927, Egas  
Moniz, neurologist and winner of the Nobel Prize in 
Physiology or Medicine (1949) for the discovery of 
leucotomy (Fusar-Poli et al., 2008), introduced cerebral 
angiography, which allowed visualizing with great accuracy 
blood vessels in and around the brain (Ligon, 2003). 
Drawbacks of these early methods were that the signal-to- 
noise ratio was poor, and that, being invasive techniques, 
the risk and discomfort for the patients were significantly 
high. 
Non-invasive structural brain imaging method was 
computerized tomography (CT), developed in the late 
1970s, when minicomputers and transverse axial scanning 
method became available. Transverse axial scanning was 
largely due to the work of Godfrey Hounsfield and Allan 
McLeod Cormack (Raju, 1999), who won the 1979 Nobel 
Prize for Physiology or Medicine for their work 
(Montgomery, 1979). With the CT available, better quality 
anatomical images of the brain became accessible to both 
clinicians and researchers. About a decade later, in the early 
1980s, a second non-invasive structural brain imaging 
method, Magnetic Resonance Imaging (MRI), was 
introduced clinically. It was developed thanks to the work of 
several researchers who buit its theoretical bases [for a 
detailed review, see (Geva, 2006)], including Peter 
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Mansfield and Paul Lauterbur. These researchers 
independently published in 1974 the technique that later 
became known as MRI (initially named Nuclear Magnetic 
Imaging – NMI), and were awarded the Nobel Prize for 
Physiology or Medicine in 2003 (Pincock, 2003). With 
regard to patient safety, MRI was superior to CT scan 
because CT scan is using ionizing radiation, while MRI uses 
harmless radio waves. Consequently, it has become the gold 
standard method to visualize non-invasively human brain 
structure, with a veritable explosion of technical refinements 
and diagnostic MR applications. 
Specifically, a number of processes have been 
introduced and developed to produce MR images. These 
processes include nuclear alignment, orthogonal Radio 
Frequency (RF) excitation, spatial encoding, and image 
formation. In simple terms, an MRI system consists of five 
major components: a) a magnet (to produce the B0 magnetic 
field for aligns protons), b) gradient systems (to spatially 
encode the positions of protons into the x/y/z axes), c) an 
RF coil system (to excite protons and perturb their 
alignment), d) a receiver (to register radio signals), and e) a 
computer system (to control the whole system and 
reconstruct the images). MRI development was based on 
knowledge that the human body is mostly made of water. 
Water molecules (H2O) contain hydrogen nuclei (protons), 
which become aligned in a magnetic field. An MRI scanner 
applies a very strong magnetic field (about 0.2 to 7 teslas, or 
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roughly a thousand times the strength of a typical fridge 
magnet), which aligns the proton "spins." The scanner also 
produces a radio frequency current that creates a varying 
magnetic field. The protons absorb the energy from the 
magnetic field and flip their spins. When the field is turned 
off, the protons gradually return to their normal spin, a 
process called precession. The return process produces a 
radio signal that can be measured by receivers in the scanner 
and made into an image. Protons in different body tissues 
return to their normal spins at different rates, so the scanner 
can distinguish among various types of tissue. The scanner 
settings can be adjusted to produce contrasts between 
different body tissues. Additional magnetic fields are used 
to produce 3D images, that may be viewed from different 
angles (Rodriguez, 2004). 
The enhancement of these non-invasive neuroimaging 
techniques (together to other subsequently developed 
imaging tools, like positron emission tomography - PET, 
electroencephalography - EEG, and 
magnetoencephalography - MEG), have enabled the in vivo 
visualization and analysis of the brain function and structure 
in unprecedented detailed manner. Moreover, they 
transformed the way we study the nervous system under 
normal and pathological conditions (Kikinis et al., 2014), 
particularly in neuropsychiatric disorders (Mayberg, 2014). 
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1.2 Neuroimaging Modalities and Technical Aspect 
 
 
Traditionally, the brain imaging modality has been 
divided into structural (Symms et al., 2004) and functional 
neuroimaging (Raichle, 2009); even if, more novel 
neuroimaging modalities provide an admixture of the two 
and do not fit pristinely into this dichotomy (e.g. Diffusion 
Tensor Imaging - DTI) (Jones and Leemans, 2011). 
Functional        neuroimaging        is        the         use 
of neuroimaging technology to measure an aspect of brain 
function, often with the aim to understanding the 
relationship between activity in certain brain areas and 
specific cognitive functions (Raichle, 2009). Common 
methods of functional neuroimaging include Positron 
Emission Tomography (PET), Functional Magnetic 
Resonance imaging (fMRI),  Electroencephalography 
(EEG), Magnetoencephalography (MEG), Functional Near- 
Infrared Spectroscopy (fNIRS), Single-Photon Emission 
Computed Tomography (SPECT) (ibidem). 
From the other side, structural neuroimaging provides  
a powerful tool to map the anatomy of the brain (Symms et 
al., 2004). Presently, there are essentially two structural 
neuroimaging modalities that are commonly used in clinical 
settings and in neuroscientific research, CT and structural 
MRI (sMRI). Both techniques yield images with excellent 
spatial resolution and contrast and are widely used to assess 
cerebral pathology in neuropsychiatric disorders. From the 
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perspective of practicing psychiatrists both techniques are 
important and they are now readily available and 
increasingly affordable. 
I focus on human brain imaging with MRI recognizing 
that other techniques (e.g. PET, SPECT and CT), 
particularly electrical (e.g. EEG, MEG and ECoG), also 
have and will continue to have an important role in 
neuroscience. 
 
 
1.2.1 Functional Magnetic Resonance Imaging 
 
 
Functional MRI (fMRI) makes use of the same 
hardware as MRI but exploits the paramagnetic properties 
of cerebral blood flow (CBF) (Villringer and Dirnagl,  
1995). The commonest method of fMRI relies on the 
variations in signal intensity that occur as a consequence of 
altered levels of cerebral blood oxygenation. This technique 
is called Blood Oxygen Level-Dependent (BOLD) contrast 
and is currently the mainstay of human neuroimaging, since 
its discover (Ogawa et al., 1990). It is based on the 
assumption that regional neural activity results in increased 
local CBF, producing an increase in oxyhaemoglobin and 
carrying red blood cells. This essentially leads to a net 
decrease in de-oxyhaemoglobin. The two molecules 
oxyhaemoglobin and de-oxyhaemoglobin have different 
magnetic properties (diamagnetic and paramagnetic 
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respectively) and the relative change in concentrations of 
the two results in a change in signal intensity (ibidem). 
Typically, fMRI is used to identify brain regions that 
are activated by a specific task performed by an individual 
whilst in the scanner (Campanella et al., 2017; D’Esposito 
et al., 1998). It is important to note, however, that it does 
not detect actual neuronal transmission but instead relies on 
the presumed coupling of neural responses to local blood 
flow. It is therefore used to assess neuro-cognitive 
processes, and the concurrent acquisition of structural MRI 
allows the regions of activity to be accurately mapped onto 
images of the brain. The advantages of fMRI over other 
techniques is that it is non-invasive and allows the study of 
brain function without the use of ionising radiation or the 
injection of radiopharmaceuticals that are used by  other 
(like PET and SPECT). In practice, fMRI can be conducted 
on most clinical 1.5 Tesla MR scanners, using conventional 
hardware, although some additional software is often 
needed. Nowadays, high field scanners (3 Tesla) are more 
common and are the preferred choice as they afford greater 
signal-to-noise ratio. In comparison to other modalities 
fMRI offers the best spatial resolution, however, it is 
susceptible to a number of artefacts, the most limiting of 
which is caused by movement. Hence, in most fMRI 
experiments it is necessary for subjects to lie extremely still 
for up to 40 min and this makes it difficult to apply to some 
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psychiatric disorders such as panic disorder and mania 
(Wylie et al., 2014). 
 
 
1.2.2 Structural Magnetic Resonance Imaging 
 
 
As mentioned before, MRI takes advantage of the fact 
that certain atoms when placed in a magnetic field align 
with the direction of the field. In an MRI scanner, this 
pattern of alignment is predictably disrupted by radio- 
frequency (RF) waves that are turned on and off 
systematically to yield pulses of energy that are then 
measured and processed into images. Hydrogen is the most 
commonly imaged element in MRI because of its abundance 
and because it gives the strongest signal. The nucleus of a 
hydrogen atom is a single spinning proton with a positive 
charge that generates a tiny magnetic field. Normally, the 
field surrounding hydrogen atoms is orientated randomly 
and together the fields of many hydrogen atoms cancel out. 
However, when in a large external magnetic field (B0) such 
as that of the MRI scanner the protons align with the 
direction of the field and precess about B0 at a frequency 
called the Larmor frequency, and lie in the RF range. If then 
an RF pulse of this frequency is directed into the tissue the 
spinning protons resonate and precess in phase. This 
generates a transverse magnetic field that precesses at the 
same Larmor frequency. When the RF pulse is switched off 
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the precessing protons induce an electromagnetic field in a 
detector coil outside the tissue that can be measured and 
subsequently powerful computers process this raw data to 
produce the MRI images (Rodriguez, 2004). 
Based on MRI principles, sMRI technique translates 
the local differences in water content into different shades of 
gray, that serve to outline different brain regions shape and 
size. The two main characteristics which govern image 
quality are spatial resolution and signal to noise ratio (SNR). 
In-plane resolution is chiefly determined by the number of 
picture 3D elements (voxel) in the frequency and phase 
encoding directions, and through-plane resolution by the 
slice thickness. SNR is determined by voxel size, slice 
thickness, scan time (including the number of phase 
encoding steps) and the sequence used. Image quality is 
therefore ultimately determined by scan time, which, in 
turn, is influenced chiefly by patients’ ability to comply 
with keeping still. 
During the last three decades, structural MRI had 
emerged as an essential tool for morphometric techniques 
(including volumetric, shape analysis, and microstructural 
techniques) (Spalletta et al., 2018). These techniques helped 
clarify in vivo some of the principal neurobiological 
characteristic of major psychiatric (Chiapponi et al., 2018; 
Dusi et al., 2018; Janiri et al., 2018), neurological and 
neurodegenerative diseases (Lipp et al., 2018; De Marco  
and Venneri, 2018; Di Paola and Bourisly, 2018; Péran et 
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al., 2018; Schrader et al., 2018), but also of normal 
population studies (Matsuda, 2018; Tamnes and Østby, 
2018) and cognitive neuroscience, in general (Morita et al., 
2016). 
 
 
 
sMRI: sequences and terminology 
 
 
The appearance of the brain on an image from an MRI 
scan is dependent on a number of interrelated factors (see 
Table 1). These include innate tissue properties that are 
described using parameters such a relaxation time and 
proton density, and are referred to as T1 and T2. Imaging 
techniques and protocols also determine the exact nature of 
the image obtained and terms that are frequently used in this 
context include sequences such as spin-echo, fast spin-echo, 
gradient-echo and echo-planar imaging with varying echo 
times (TE), flip angles and repetition times (TR). A T1- 
weighted image has a short TR and short TE such that 
tissues with a short T1 relaxation time appear bright and 
those with a long T1 appear dark. On a T2-weighted image 
that has long TR and long TE, tissues with a short T2 
relaxation time are dark and those with a long T2 are bright 
(Rodriguez, 2004). 
Images from conventional T1-weighted (T1-w) and 
T2-weighted (T2-w) MRI sequences, are characterized by a 
high contrast and spatial resolution, being widely used to 
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Table 1 
CSF: cerebral-spinal fluid; 
investigate structural properties of the brain (Ganzetti et al., 
2015), used for volumetric study (Spalletta et al., 2018). 
Pathological processes are therefore most often described in 
terms of T1 and T2 signal behavior that results in a 
computer-generated image with a highly detailed map of the 
brain’s tissues and structures. Thus, this tool can be used to 
discover the presence of abnormal tissue through the 
changes in tissue density or composition. Scientists, 
clinician and neuroradiologist examining an sMRI can 
readily distinguish between gray and white matter and other 
types of tissue—both normal, such as blood vessels, and 
abnormal, such as tumors—by their different shading and 
contrast with surrounding areas. 
 
 
 
A third commonly used sequence is the Fluid 
Attenuated Inversion Recovery (FLAIR). FLAIR  images 
are heavily similar to T2-weighted images, except that the 
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TE and TR times are very long. By doing so, abnormalities 
remain bright but normal CSF fluid is attenuated and made 
dark. It has been introduced as a complement of, or even a 
replacement for, the conventional T2-weighted sequence. 
Indeed, setting to null fluids using an inversion time that 
effectively suppresses hyperintense signals from free water 
in cerebrospinal fluid (CSF), FLAIR sequences allow to 
highlight hyperintense coming from tissues’ lesions (De 
Coene et al., 1992). Hence, this sequence is very sensitive to 
pathology and makes the differentiation between CSF and 
an abnormality much easier (Fukuoka et al., 2010; Iorio et 
al., 2013; Sati et al., 2012). 
 
 
 
1.2.4 Diffusion Neuroimaging 
 
 
A more recent brain imaging technique, which has 
emerged from advances in MRI, is that of Diffusion 
Weighted Imaging (Bammer, 2003) and Diffusion Tensor 
Imaging (Mori and Zhang, 2006) (respectively, DWI and 
DTI). These last takes advantage from specific MRI 
sequences as well as software that uses the diffusion of water 
molecules to generate contrast in MR images. 
Diffusion weighted imaging is an MRI modality that 
enables the quantification of the diffusion of water in tissue 
making it possible to investigate microstructural aspect of 
the white matter, within the brain. It is predicated on the fact 
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that anatomical structures such as cell membranes, myelin 
sheaths, as well as intracellular micro-organelles act as 
barriers to the diffusion and free movement of water thus 
limiting the spatial flow of these molecules. The 
arrangement of axons in parallel bundles with myelin 
sheaths facilitates the diffusion of water molecules 
longitudinally, preferentially along their main direction. 
Such preferentially oriented diffusion is called anisotropic 
diffusion (Mori and Zhang, 2006). By acquiring a 
conventional diffusion weighted MRI in at least six non- 
collinear directions it is possible to reconstruct the brain’s 
underlying neuronal microstructure that is normally 
‘invisible’ using conventional MRI (Schilling et al., 2017). 
A special kind of DWI, DTI, has been used  
extensively    to    investigate    and    to    map white   
matter microstructural integrity and tractography in the 
brain (Davis et al., 2009; Lazar et al., 2003; Melhem et al., 
2002). Tractographic reconstruction of neural connections 
via DTI is based on an extension of diffusion MRI 
properties. Indeed, if a series of diffusion gradients (i.e. 
magnetic field variations in the MRI magnet) are applied in 
a fashion that can determine at least 3 directional vectors 
(use of 6 different gradients is the minimum and additional 
gradients improve the accuracy for "off-diagonal" 
information), it is possible to calculate, for each voxel, a 
tensor (i.e. a symmetric positive definite 3×3 matrix) that 
describes the 3-dimensional shape of diffusion (Mori and 
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Zhang, 2006; Mori and van Zijl, 2002; Schilling et al., 
2017). Specifically, the fiber direction is indicated by the 
tensor's main eigenvector. This vector can be color-coded, 
yielding a cartography of the tracts' position and direction 
(red for left-right, blue for superior-inferior, and green for 
anterior-posterior) (Alexander et al., 2007; Jones and 
Leemans, 2011). Characterization of each eigenvalue (l) in 
the  tensor  and  combinations  (see.  Table  2)  of   them 
help constitute the main diffusion measures, offering 
information of microstructural aspects. In DTI studies, there 
are four measures that are most commonly used; fractional 
anisotropy (FA), mean diffusivity (MD), axial diffusivity 
(AD) and radial diffusivity (RD). Specifically, in axial 
diffusivity (AD) we only quantify the value of l1. While in 
radial    diffusivity    (RD)    we     take     the     average     
of l2 and l3. Mean diffusivity (MD) provides an average of 
all. And finally, fractional anisotropy (FA) provides the 
relative difference between the largest eigenvalue as 
compared to the others. These measures are commonly used 
clinically to localize white matter lesions that do not show 
up on other forms of clinical MRI (Alexander et al., 2007). 
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Table 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A further advance of DTI is its application to non- 
invasively construct 3D trajectories of neural tracts in-vivo, 
using tractographic techniques (Lazar et al., 2003). 
Specifically, fiber tracking algorithms can be used to track a 
fiber along its whole length (e.g. the corticospinal tract, 
through which the motor information transit from the motor 
cortex to the spinal cord and the peripheral nerves). 
Tractography is a useful tool for measuring deficits in white 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CSF: cerebrospinal fluid; WM: white matter; SNR: signal-to-noise ratio; FA: Fractional 
Anisotropy; MD: Mean Diffusivity; AD: Axial Diffusivity; RD: Radial Diffusivity; l: 
eigenvalue 
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matter, such as in aging (Davis et al., 2009). Its estimation 
of fiber orientation and strength is increasingly accurate, and 
it has widespread potential implications in the fields of 
cognitive neuroscience and neurobiology. Tractography also 
allows the modelling of white matter neural connectivity, a 
method that is currently the subject of intense investigation 
as it can provide information relating to neuronal 
connections (Rubinov and Sporns, 2010). At this point in 
time the ability of DTI to characterize the white matter 
architecture of the brain is unparalleled by any other 
imaging modality. 
 
 
2. Structural Neuroimaging in Psychiatric Disorders 
 
 
Advances in neuroscience have revolutionized our 
understanding of the central nervous system leading to new 
insights into the complex anatomical, physiological, 
biochemical, genetic, and molecular organizational structure 
of the human brain. Specifically, neuroimaging technologies 
have enabled the investigation of normal brain 
function/structure and are being used to gain important new 
insights into the mechanisms behind many neuropsychiatric 
disorders. Indeed, since the demonstration, in 1976, that 
patient with schizophrenia had enlarged cerebral ventricles 
(Johnstone et al., 1976), psychiatry was pushed in a new era 
where neuroimaging would help it identify mental disorders 
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and ultimately clarify their mechanisms. Thanks to 
structural brain neuroimaging, it is now widely  accepted 
that schizophrenia is a neurodevelopmental disorder with 
neurobiological evidence (Chiapponi et al., 2018). The fact 
that structural changes occur and are discernible with 
neuroimaging methodologies has assisted in unravelling the 
pathophysiology of schizophrenia, and of other major 
psychiatric condition, like mood disorders (Janiri et al., 
2018). 
The research applications of neuroimaging in 
psychiatry, however, have to compound to several issues, 
intrinsically related to psychiatric illness. Indeed, they are 
usually primarily diagnosed by careful assessment of 
behavior combined with subjective reports of abnormal 
experiences to group patients into disease categories, that 
mask substantial heterogeneity. For example, a diagnosis of 
schizoaffective disorder is often given to people with 
episodes of both affective and psychotic symptoms, (either 
alternating or occurring together) which casts some doubt 
on the traditional dichotomy delineating affective and 
psychotic disorders into discrete illness categories 
(Craddock and Owen, 2005). In the absence of definitive 
and objective biomarkers of pathophysiological processes 
underlying behaviors associated with  conventionally 
defined psychiatric illness categories, and because of the 
heterogeneity within, and considerable overlap between, 
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these behaviors, appropriate diagnosis and treatment are 
difficult for many psychiatric illnesses. 
Bipolar disorder is an especially good example of a 
group of psychiatric illnesses that are difficult to diagnose 
accurately. For example, although this disorder, along with 
other psychiatric illnesses, is one of the ten most debilitating 
of all non-communicable diseases (Department of Health 
Statistics and Informatics, 2008), misdiagnosis of the illness 
as recurrent unipolar depression occurs in 60% of patients 
seeking treatment for depression (Goodwin and Jamison, 
2012; Hirschfeld et al., 2003). Moreover, bipolar disorder 
types I and II are especially difficult to diagnose accurately 
in clinical practice, particularly in their early stages. Only 
20% of patients with bipolar disorder who are experiencing 
a depressive episode are diagnosed with the disorder within 
the first year of seeking treatment (Hirschfeld et al., 2003), 
and the mean delay between illness onset and diagnosis is 
5–10 years (Baldessarini et al., 2007). A major reason for 
the difficult diagnosis is the challenge of differentiating 
bipolar disorder type I or II from unipolar depression — an 
illness characterized by recurrent depressive episodes — 
especially in patients who present during a depressive 
episode and in those with no clear history of mania or 
hypomania (Goodwin and Jamison, 2012; Hirschfeld et al., 
2003). This is further compounded by comorbid anxiety 
(Simon et al., 2004), substance misuse (Cassidy et al., 
2001). 
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Neuroimaging technologies being used to gain 
important new insights into the mechanisms behind bipolar 
disorders. Limbic and cortical areas and circuits that are 
implicated in the generation and regulation of emotion have 
been the main focus in neuroimaging research, since they 
can be readily visualized and investigated using structural 
techniques. Hence, mood disorders, in general, and bipolar 
disorder neuroimaging research in particular, is now a 
substantive and promising field. The research applications 
of neuroimaging in bipolar disorder aim to relate 
psychopathology to structural and functional aspects of the 
brain and can be broadly viewed as having either a 
restructuring or refining role. Restructuring involves 
dispensing with the current psychiatric phenomenological 
entities and replacing these with biologically driven 
explanations based on neuroscientific findings. In contrast, 
refining involves generally maintaining the current 
categories of psychiatric disorders but validating their 
essential elements by providing a neural substratum. Both 
approaches find support in the many studies that have been 
conducted in bipolar patients populations. 
 
 
 
3.1 Structural Neuroimaging in Bipolar Disorder 
 
 
In DSM-5, bipolar and related disorders, as they are 
now called, are given a chapter on their own, that includes 
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bipolar I disorder, bipolar II disorder and cyclothymic 
disorder (American Psychiatric Association. DSM-5 Task 
Force., 2013). While in the past only a distinct period of 
abnormally and persistently elevated, expansive or irritable 
mood was necessary, these symptoms now have to be 
present in combination with persistently increased (goal- 
directed) activity or energy, most of the day, nearly every 
day. 
Bipolar Disorder (BD) is a mood disorder that confers 
considerable individual and societal morbidity and cost 
(Gardner et al., 2006). Patients with BD experience 
recurrent episodes of marked mood changes, which last for 
at least a week, and may continue for months. These 
episodes consist of periods of mania or hypomania, 
depression, or mixed mood, interspersed with periods of 
normal mood (euthymia) (Belmaker, 2004). A significant 
body of evidence suggests that BD has a strong 
neurobiological basis and structural brain abnormalities in 
BD have been reported (Hallahan et al., 2011; Hibar et al., 
2016), even if the pattern of these brain abnormalities based 
on magnetic resonance imaging is still not clearly defined. 
 
 
White Matter 
 
 
White matter (WM) abnormalities are one of the most 
consistently reported findings in neuroimaging studies of 
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BD (Vederine et al., 2011). Indeed, the presence of white 
matter hyperintensities (WMH) on T2-weighted and FLAIR 
MRI scans was confirmed in several neuroimaging studies 
(Altshuler et al., 1995; Gulseren et al., 2006). Although the 
pathogenesis of WMH is not completely understood, at least 
some are likely to reflect vascular ischemia and are 
associated with cardiac risk factors and normal ageing 
(Matsusue et al., 2006). Despite the association with age, a 
number of studies have reported WMH in young patients 
with bipolar disorder (Altshuler et al., 1995; Breeze et al., 
2003; Lyoo et al., 2002; Silverstone et al., 2003). They 
appear particularly significant in affective disorder, having 
been associated high rates of suicidality (Pompili et al., 
2007). 
DTI studies are a more recent promising approach for 
the investigation of WM microstructural biomarkers and 
endophenotypes in BD. The first whole-brain DTI studies 
generated heterogeneous results concerning the type of FA 
variation (increase or decrease) and the precise location of 
these changes. Some studies have reported a localized 
(Bruno et al., 2008; Liu et al., 2010; Sussmann et al., 2009) 
or diffuse decrease in FA (Chan et al., 2010; Kafantaris et 
al., 2009; Zanetti et al., 2009), whereas others have reported 
an increase in FA in diffuse regions (Michèle et al., 2009)  
or a mixture of increases and decreases in FA (Mahon et al., 
2009; Versace et al., 2008). This may reflect different 
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methodological approaches and heterogeneity within the 
clinical populations studied. 
Review studies (Brambilla et al., 2009; Heng et al., 
2010; Mahon et al., 2010; Sexton et al., 2009; Womer et al., 
2009) and meta-analysis (Vederine et al., 2011) of DTI 
studies in BD have tried to summarize the results, even if 
several issues are still unaddressed. 
 
Gray Matter 
A number of studies have examined structural gray 
matter characteristics in cortical and subcortical regions of 
adults with BD. Many of them was conducted by means of 
volumetric measurements of regional brain structures and 
the results often showed inconsistent findings (Arnone et 
al., 2009; McDonald et al., 2004b). Specifically, previous 
studies in BD patients have examined cortical regions 
implicated in emotion processing and cognitive processes 
that are important for emotion regulation, including the 
cingulate cortex as well as frontal and temporal regions 
(Lyoo et al., 2004; Nugent et al., 2006; Wilke et al., 2004). 
Prefrontal cortical gray matter volumes had been found to 
decrease with illness progression (Kalmar et al., 2009) but 
normalize (or even increase) with treatment (Moore et al., 
2000, 2009). Studies have also reported widespread 
decreases in frontal cortical thickness bilaterally, especially 
in the right hemisphere, and abnormally decreased temporal 
and parietal cortical thickness bilaterally in adults with 
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bipolar disorder (Foland-Ross et al., 2011; Rimol et al., 
2010). 
A second key finding relating to emotion processing 
and regulation neural circuits is decreased subcortical deep 
gray matter structures. Specifically, abnormally decreased 
hippocampal and parahippocampal volumes have been 
reported in adults with bipolar disorder (Almeida et al., 
2009; Rimol et al., 2010; Wijeratne et al., 2013), although 
such abnormalities may be masked or compensated by 
treatment (Foland et al., 2008; Hajek, Kopecek, et al., 2012; 
Hallahan et al., 2011). 
Although volumetric analyses of structural brain 
imaging data have been a mainstay of brain structure 
investigations in BD, in recent years methodological 
developments have led to structural measures that can 
supplement them. Specifically, recent studies in BD 
reported changes in shape of the surface of the caudate 
nucleus (Ong et al., 2012), putamen, ventral striatum and 
thalamus (Womer et al., 2014). Shape analysis enables the 
uncovering of localized deformations on the surface of a 
brain structure and it may more precisely identify impaired 
morphologies within the brain. This is particularly important 
in the study of brain structures with explicit regional 
differentiation in functions, such as thalamus or striatum 
(Herrero et al., 2002), that are central subcortical areas 
involved in BD (Womer et al., 2014). 
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The variability of the results is still predominant in BD 
literature findings (McDonald et al., 2004) and perhaps 
unsurprising given the enormous clinical heterogeneity (e.g. 
in illness subtype, mood-state, medication status, illness 
severity and duration, etc.) and small size of samples 
studied. For instance, one much debated source of bias in 
the study of brain volumetric associations with BD is the 
effect of mood-stabilizing medications, primarily lithium, 
which may influence brain structure (Hartberg et al., 2015; 
Hibar et al., 2016). Neuroimaging studies are promising 
components for a new diagnostic framework for BD, but a 
major issue is the potential confound of psychotropic 
medication upon experimental measures. Withdrawing all 
individuals from medication and examining only 
unmedicated individuals may be clinically unfeasible and 
may render findings less generalizable. Ideally, comparisons 
of medicated with unmedicated individuals should be 
included in cross-sectional functional neuroimaging studies 
of bipolar disorder. 
The present work aimed to address these specific 
aspects. Specifically, study 1 investigated the trajectories of 
grey and white cerebral volumetry in bipolar disorder 
progressions, while study 2 and 3 assessed the impact of 
pharmacological treatment with lithium on subcortical 
structures volumetry and shape, respectively. 
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CHAPTER 2 
 
 
 
Study 1: Gray and white matter trajectories in patients 
with bipolar disorder 
 
 
 
2.1 Introduction 
 
As stated above, although several structural 
abnormalities in the cortical, subcortical, and limbic systems 
of patients with bipolar disorder (BD) have been 
documented, the findings are often inconsistent. For 
example, gray matter (GM) volumes of several structures, 
including the cingulate cortex as well as frontal and 
temporal regions, have been found to be reduced (Lyoo et 
al., 2004), to be increased (Adler et al., 2007), or to show no 
differences (McDonald et al., 2005) when compared with 
healthy control subjects (HC). Furthermore, two large meta- 
analyses of cross-sectional structural imaging studies of 
patients with BD also yielded inconclusive results. In 
particular, Kempton and colleagues (Kempton et al., 2008) 
described increased brain ventricular volumes and corpus 
callosum atrophy, while Arnone and colleagues (Arnone et 
al., 2009) found significant whole-brain and prefrontal lobe 
reductions. More recently, Selvaraj and collaborators 
(Selvaraj et al., 2012) found neuroanatomical abnormalities 
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in the right prefrontal cortex, anterior cingulate cortex, 
insula, and claustrum in patients with BD. Some voxel- 
based morphometry (VBM) studies highlighted regional and 
global reductions in white matter (WM) volume and density 
(Chen et al., 2004; Davis et al., 2004), while others failed to 
replicate these findings (López-Larson et al., 2002; Scherk 
et al., 2008). This mirrors the lack of concordance found in 
GM studies. 
Although longitudinal studies yielded more consistent 
findings of progressive atrophy of the prefrontal cortex, 
anterior cingulate cortex and subgenual region, they yet 
again reported less consistent findings for temporal and 
related regions, such as the hippocampus (Lim et al., 2013). 
To understand which brain abnormalities are present from 
the very beginning of the disorder and to evaluate how they 
change during the illness course, it is fundamental to assess 
patients with BD over a long-time span. It is also necessary 
to have a long observational period to determine whether  
the ageing process affects patients with BD and HC 
differently. Thus, to address all these critical issues, this 
work employed a cross-sectional case-control study to 
compare structural brain abnormalities at different ages 
(hereafter called trajectories) in patients with BD and HC 
over a time period of about 50 years. 
The primary aim of the present study was to  
understand whether WM and GM changes were present 
from the beginning of the illness and whether they 
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continued to be present over the course of the illness. Since 
patients with bipolar disorder types I (BD-I) and II (BD-II) 
have different symptomatology and severity, preliminarily 
we compared trajectories between the two subgroups to 
verify their homogeneity and investigate shared and unique 
diagnosis-related neuro-anatomical abnormalities. 
 
 
 
2.2 Methods and Materials 
 
 
The study was approved and undertaken in accordance 
with the guidelines of the Santa Lucia Foundation Ethics 
Committee. All participants gave their written informed 
consent to participate in the research after they had received 
a complete explanation of the study procedures. 
G*Power statistical software (Erdfelder et al., 2009), 
was used to compute power analysis. Results shown that a 
sample size of at least 19 would have greater than 80% 
power to detect a difference between groups with an alpha 
value of <0.05 (two tailed). 
 
 
 
Participants 
 
 
Consecutive patients with a diagnosis of BD according 
to the Diagnostic and Statistical Manual of  Mental 
Disorders IV-Edition, Text Revised (DSM-IV-TR) 
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(American Psychiatric Association, 2000) were assessed at 
the Santa Lucia Foundation in Rome, between January 2012 
and January 2015. Inclusion criteria for all participants 
were: (i) age between 18 and 75 years, (ii) at least five years 
of education, and (iii) suitability for magnetic resonance 
imaging (MRI) scanning. Exclusion criteria were: (i) history 
of alcohol or drug abuse in the two years before the 
assessment, (ii) lifetime drug dependence, (iii) traumatic 
head injury with loss of consciousness, (iv) past or present 
major medical illness or neurological disorders, (v) any (for 
HC) or additional (for patients with BD)  psychiatric 
disorder or mental retardation, (vi) dementia or cognitive 
deterioration according to DSM-IV-TR criteria, and Mini-
Mental State Examination (MMSE) (Folstein et al., 1975a) 
score < 25, consistent with normative data in the Italian 
population (Measso, G., Cavarzeran, F., Zappalà, G., 
Lebowitz, B. D., Crook, T. H., Pirozzolo, F. J., ... & 
Grigoletto, 1993), and (vii) any potential brain abnormality 
or microvascular lesion as apparent on conventional fluid 
attenuated inversion recovery (FLAIR) scans; in particular, 
the presence, severity, and location of vascular lesions were 
computed according to the semi-automated method recently 
published by Santa Lucia Foundation neuropsychiatric 
research (Iorio et al., 2013). 
All patients were recruited at three sites: the Lithium 
Clinic at Sant’Andrea Hospital, Villa Von Siebenthal, and 
the Santa Lucia Foundation in Rome. The clinical 
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psychiatrist who had been treating the patients and knew 
their clinical history, and who was blind to the aims of the 
study, made the preliminary diagnosis using the DSM-IV- 
TR criteria. All clinical diagnoses were confirmed by a 
research psychiatrist using the Structured Clinical Interview 
for DSM-IV-TR-Patient Edition (SCID-I/P) (First et al., 
2002). If the diagnoses made at the two different steps were 
not consistent, more data were gathered and the diagnostic 
process continued until a final diagnostic consensus was 
reached. If an agreement could not be reached, the patient 
was removed from the sample. 
The researchers involved in the assessment of the 
patients completed an intensive training program in 
preparation. The training program consisted of bi- or tri- 
weekly eight-hour sessions where junior researchers 
assessed the patients under the continuous supervision of a 
senior researcher. The training program lasted from three to 
six months, and did not end until all the researchers were 
able to make a psychopathological and neuropsychological 
assessment achieving good inter-rater reliability (k ≥ 0.8). 
Eighty-five patients with BD were initially included in 
the present study. Of the original group of patients, three 
refused to undergo the MRI exam and four were excluded 
for the presence of moderate to severe brain vascular lesions 
(see exclusion criteria). The remaining sample of 78 patients 
included 49 with BD-I and 29 with BD-II.
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We also recruited 78 HC in the same geographical 
area. They were carefully matched with the patients for age 
(2 years), gender, and educational level (2 years). All HC 
were screened for a current or lifetime history of DSM-IV- 
TR Axis I and II disorders using the SCID-I-NP ) (First et 
al., 2002) and SCID-II (M. B. First et al., 1997); they were 
also assessed to confirm that no first-degree relative had a 
history of mood - or schizophrenia-related disorders. 
The overall severity of affective symptoms was 
assessed using the 17-item Hamilton Depression Rating 
Scale (HDRS) (Hamilton, 1960) and the Young Mania 
Rating Scale (YMRS) (Young et al., 1978). Age at onset 
was defined as ‘age at onset of first affective symptoms’, 
which were investigated in an interview with patients and 
first-degree relatives. All patients were under stable 
pharmacologic treatment for at least six months, usually 
polipharmacy, including treatment with antidepressants, 
mood-stabilizing agents, and stable oral dosages of one or 
more antipsychotics (data not shown; available upon 
request). 
 
Image acquisition and processing 
 
 
All 156 participants underwent the same 
imagingprotocol, which included 3D T1-weighted, T2- 
weighted and FLAIR sequences using a 3T AllegraMR 
imager (Siemens, Erlangen, Germany) with a standard 
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quadrature head coil. Whole-brain T1-weighted images 
were obtained in the sagittal plane using a modified driven 
equilibrium Fourier trans-form sequence (echo 
time/repetition: time=2.4/7.92msec, flip angle=15°, voxel 
size=19191mm3). T2 and FLAIR sequences were acquired 
to screen for brain pathology. 
T1-weighted images were processed and examined 
using SPM8 software (Wellcome Department of Imaging 
Neuroscience Group, London, UK; 
www.fil.ion.ucl.ac.uk/spm) and specifically the VBM 
toolbox VBM8 (http://dbm.neuro.uni-jena.de/vbm.html) 
running in Matlab2007b (MathWorks, Natick, MA, USA). 
VBM8 extends the unified segmentation model (Ashburner 
and Friston, 2005) consisting of MRI field intensity 
inhomogeneity correction, spatial normalization and tissue 
segmentation at several pre-processing steps to further 
improve data quality. The segmented GM and WM maps 
were registered to the Montreal Neurological Institute 
(MNI) space using the iterative high-dimensional 
normalization approach provided by the Diffeomorphic 
Anatomical Registration Through Exponentiated Lie 
Algebra (DARTEL) (Ashburner, 2007) toolbox. The 
normalized tissue maps were written with anisotropic voxel 
resolution of 1.5 x 1.5 x 1.5 mm3. The tissue deformations 
were then used to modulate participants’ GM and WM 
maps. Finally, the modulated and normalized GM and WM 
segments were smoothed with an 8-mm full-width half- 
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maxi-mum Gaussian kernel. The segmented, normalized, 
modulated and smoothed GM and WM images were used 
for analyses. 
 
 
 
 
Statistical analyses 
 
 
Comparisons between the diagnostic groups on 
sociodemographic characteristics (age, gender, and 
educational level) were performed using the t-test or chi- 
square test. 
Factorial analysis of covariance (ANCOVA) was used 
to compare, at the voxel level, the potential age-related 
changes in terms of brain volume, evaluated in GM and 
WM, between diagnostic groups. For both tissues, volume 
was the dependent variable, and diagnosis was included as a 
fixed factor (independent variable), and age as a covariate. 
We did not include illness duration as a regressor in the 
ANCOVA model since it was strongly collinear with age 
(R=0.65) and the presence of collinear regressors could 
reduce the strength of results (Berk, 1977). We first verified 
the linear dependence between volume and age, the primary 
hypothesis of ANCOVA. Then, we verified the ANCOVA 
assumption of homogeneity of regression slopes, i.e., we 
looked for the absence of any interaction between diagnosis 
and age. Where this hypothesis was fulfilled, we looked for 
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the presence of a main effect of the diagnosis. To avoid type 
I errors (i.e., accepting false positives) all these analyses 
were performed using the family-wise error (FWE) 
correction (p<0.05), which controls for the possibility of any 
false positives across the entire volume (Ashburner and 
Friston, 2005). In addition, results were considered 
statistically significant if they were part of a spatially 
contiguous cluster of 30 voxels or greater. As already 
mentioned, we used the normalized and modulated images 
for the analysis, which already accounted for different head 
sizes in the data. Therefore, there was no need for further 
corrections for head size in the statistical model. 
Before comparing age-related trajectories between the 
whole group of patients with BD and HC, we first 
determined whether there was any difference in the age- 
related trajectories followed by GM and WM volumes 
between the two subgroups of patients, i.e., those with BD-I 
and BD-II. In this case, the comparisons were performed at 
the significance level of p<0.05, uncorrected for multiple 
comparisons, in order to avoid type II errors (i.e., rejecting 
false negatives) in the final results. These groups were not 
different for age and gender, but were different for illness 
duration (Table 1) and we therefore included this  
continuous variable in the ANCOVA model to correct for  
its potential effect. 
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4.4 Results 
 
 
Sociodemographic and clinical characteristics 
 
 
Sociodemographic and clinical characteristics of the 
patients are shown in Tables 1 and 2. The youngest patient 
was 21 years old, and the oldest was 72 years old. 
Specifically, we had 13 patients in the 21–30 years age 
group, 20 patients in the 31–40 years age group, 15 patients 
in the 41–50 years age group, 21 patients in the 51–60 years 
age group, six patients in the 61–70 years age group, and 
three patients in the 71–75 years age group. The groups of 
patients with BD-I and BD-II and the group of HC did not 
significantly differ for age, gender, and educational level, 
but the BD-I and BD-II groups differed for illness duration. 
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Age-related gray matter trajectories 
 
 
When comparing age-related GM trajectories between 
patients with BD-I and BD-II, we did not find GM voxels 
with either a significant interaction between diagnosis and 
age or a main effect of diagnosis, indicating that the age- 
related GM trajectories of both patient subgroups were 
indistinguishable for all GM voxels. We therefore analyzed 
the two BD subtypes as one group and continued comparing 
age-related trajectories between patients with BD and HC. 
In the ANCOVA comparing patients with BD and HC, the 
test for voxel-wise linear dependence between GM volume 
and age revealed a negative linear correlation (p<0.05) in 
clusters distributed in the entire GM in both BD and HC. 
While no interaction between diagnosis and age emerged, 
the ANCOVA analysis unveiled a significant (p<0.05, 
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FWE-corrected) main effect of diagnosis in four clusters.  
As shown in Figure 1 and described in Table 3, one cluster 
was localized in the posterior cingulate cortex (PCC), one in 
the right thalamus and two clusters were localized  
bilaterally in the cerebellum. In order to identify which 
thalamic area the cluster in the thalamus belonged to, we 
employed the probabilistic thalamic Connectivity Atlas 
(Johansen-Berg et al., 2004) 
(http://www.fmrib.ox.ac.uk/connect) that divides the 
thalamic structure according to the projections to different 
cortical regions, and it emerged that the whole cluster 
belonged to the thalamic area projecting to the temporal 
lobe. 
Analogously, to obtain the precise anatomical 
localization of clusters in the cerebellum, we superimposed 
our results onto Diedrichsen’s probabilistic atlas, which 
subdivides the cerebellum into 10 different regions 
(Diedrichsen et al., 2009), and it appeared that the cerebellar 
clusters belonged bilaterally to lobules I–IV (see Table 3). 
In particular, the ANCOVA results suggested that the GM 
age-related trajectories of the two diagnostic groups were 
parallel (no interaction) and that they were significantly 
different starting from the youngest age (main effect of 
diagnosis). To confirm this, we calculated the mean GM 
intensity for each subject in those regions where an effect of 
diagnosis emerged and plotted the mean GM intensity as a 
function of age for the two groups. As shown in Figure 1, 
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the patients had reduced GM with respect to HC in the 
entire age range considered. In each cluster, the slopes of 
the linear regressions fitting the data of the two diagnostic 
groups were significant (p<0.05) and, as the absence of 
interaction between diagnosis and age suggested, 
statistically indistinguishable. 
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Age-related white matter trajectories 
 
 
In accordance with results found in GM, WM 
trajectories of patients diagnosed with BD-I and BD-II were 
indistinguishable for all WM voxels. Therefore, we 
compared age-related trajectories between the whole BD 
group and HC. We first tested for the voxelwise linear 
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dependence between whole-brain WM and age inpatients 
with BD and HC, and we found a negative correlation 
(p<0.05) in both groups for all WM voxels. While no 
interaction between diagnosis and age emerged, the 
ANCOVA revealed a main effect of diagnosis in one cluster 
[1,242 voxels, Z-score=5.18, p (FEW-corrected) <0.0001] 
with the statistical peak localized in the left posterior limb 
of the internal capsule (MNI coordinates: x=-26, y=-13, z=- 
2) (see Fig. 2). In particular, the ANCOVA results indicated 
that the WM age-related trajectories of the two diagnostic 
groups were parallel (no interaction) and that they were 
significantly different starting from the youngest age (main 
effect of diagnosis). Figure 2 shows that patients had 
reduced WM with respect to HC in the whole age range 
considered. The fitted linear regressions were both 
significant  (pBD=0.006  and  pHC=0.02),  Pearson’s 
correlations were rBD=-0.31 and rHC=-0.26, and the slopes 
were slopeBD=-0.0017 and slopeHC=-0.0013). 
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2.4 Discussion 
 
 
The aim of this study was to investigate the presence of 
structural brain abnormalities at different ages in patients 
affected by BD and to compare them to those in HC. The 
present work was based on cross-sectional case–control 
comparisons. 
Previous studies have already used a cross-sectional 
design to evaluate brain modifications over a span of time in 
patients diagnosed with schizophrenia (Chiapponi et al., 
2014), BD (Lopez-Larson et al., 2010), major depressive 
disorder (Hagan et al., 2015), and autistic spectrum disorder 
(Greimel et al., 2013). Our results revealed age-related 
atrophy in GM and WM volumes in both patients and HC, 
as already found in a previous large study focused on 
patients with BD-I in the euthymic phase (Emsell et al., 
2013). With respect to HC, patients with BD showed a 
reduced brain volume in areas comprising the PCC (BA23) 
bilaterally, the right thalamus, the bilateral cerebellum and 
the left posterior limb of the internal capsule. The fact that 
these areas were permanently reduced over the entire age 
range investigated here suggests that brain alterations are 
present from the very early phase of the disorder, and that 
the brain alterations are not the results of a 
neurodegenerative process. 
All cerebral areas where a main effect of diagnosis was 
found are involved in the regulation of two important 
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dimensions in BD: mood/emotion and psychomotricity. The 
PCC plays a central role in the default mode network 
(DMN) (Buckner et al., 2007). PCC and DMN 
abnormalities are present in a wide range of neurological 
and psychiatric disorders (Buckner et al., 2007; Leech and 
Sharp, 2014), including mood disorders. Specifically, 
several MRI studies have reported abnormal functional 
activity in major depression, although the abnormalities 
reported are variable (Berman et al., 2011; Bluhm et al., 
2009; Zhou et al., 2010; Zhu et al., 2012). Studies on 
patients with BD are still scarce and results are inconsistent. 
Compared to HC, volumes of PCC in patients with BD were 
found to be increased (Adler et al., 2007), unchanged (Sassi 
et al., 2004) or decreased (Atmaca et al., 2007; Kaur et al., 
2005). Consistent with the findings of a previous report 
(Kaur et al., 2005), here we found that the volume of the 
PCC was decreased from the very early phase of the  
disease. 
The thalamus, a fundamental relay station that connects 
cortical and subcortical structures as well as different 
cortical regions, has been reported to be functionally 
involved in the modulation of emotions, cognition and 
social behavior (Strakowski et al., 2005). There is an 
important heterogeneity in the findings of thalamic volume 
alterations in patients with BD (Ng et al., 2009). To 
summarize, the majority of studies reported no significant 
volumetric or GM thalamic differences in patients with BD 
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compared to HC, while few other studies found either 
increased or decreased thalamic volume. Our data are in line 
with the latter studies. In particular, we found a volume 
reduction in the thalamic area projecting to the temporal 
pole, hippocampal formation, and amygdala (Behrens et al., 
2003). It is noteworthy that these structures are part of the 
limbic system, a group of interconnected are as that 
classically have been thought to be involved in control of 
emotions and episodic memory. Recently, a new model of 
the limbic system has been proposed and it was noted that 
the alterations of the temporo-amygdala-orbitofrontal 
network are often present in patients affected by several 
psychiatric conditions (Catani et al., 2013). According to 
present findings, it is possible to hypothesize that these 
alterations in patients with BD are associated with 
abnormalities in that specific thalamic subregion. 
Our findings involving the cerebellum are intriguing, 
considering its role in the regulation of mood and emotions. 
Both structural and functional abnormalities were found in 
the cerebellum of psychiatric patients (Hoppenbrouwers et 
al., 2008). Reduced volumes of the vermis and other 
cerebellum abnormalities have been found in patients 
affected by BD (Hoppenbrouwers et al., 2008; Kim et al., 
2013; Mills et al., 2005), even though a recent study did not 
confirm this result (Laidi et al., 2015). We found a 
decreased volume of the anterior cerebellar lobules, which 
are primarily involved in the motor control system. 
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Although BD is classified as an affective disorder, 
psychomotor alterations are classic clinical signs  
(Kraepelin, 2014), present in different phases of the disease, 
and the focus of clinical (Parker et al., 1994; Sani et al., 
2014), neuropsychological (Bora et al., 2007) and 
neurobiological investigations (Liberg et al., 2014; Walther 
et al., 2012). In contrast to a previous report (Kim et al., 
2013) describing how the damage to the posterior cerebellar 
regions appears to progress over the course of illness (but 
could potentially be delayed and/or reversed by appropriate 
pharmacological treatment), in our sample, the reduction of 
volume was present from the beginning and remained stable 
during the course of the illness. This suggests that the 
reduction of cerebellar volume is due to the illness and, 
following pharmacological treatment, remains stable over 
time. However, an apparent independence of cerebellar 
volume from pharmacological treatments, such as lithium or 
antipsychotics, was found in a recent large international 
study (Laidi et al., 2015). In the WM context around the 
thalamus, we found a decreased density of the WM fibers of 
the posterior limb of the internal capsule. The posterior limb 
of the internal capsule mostly includes the fibers of the 
corticospinal tract (CST), which contains ascending fibers 
from the thalamus to the cerebral cortex and descending 
fibers from the fronto-parietal cortex to the subcortical 
nuclei and spinal cord. It conveys information among 
primary and secondary motor areas, the thalamus, the 
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prefrontal cortex and the cerebellum. Moreover, this system 
is involved both in motor functions and in cognition and 
emotional regulation in individuals at high genetic risk for 
(Sprooten et al., 2011) or in the early phase of BD (Lu et  
al., 2011). Alterations of the CST were found in previous 
DTI studies, although the results are inconsistent (Mahon et 
al., 2009; Paillère Martinot et al., 2014). In any case, our 
data confirm that the CST is involved in the mechanisms of 
BD and suggest that the alteration of the CTS may be 
considered as part of the more general WM connectivity 
alterations found in patients with BD (Mahon et al., 2010). 
It is intriguing that all the cerebral areas showing a 
volume reduction are part of the two main brain networks 
involved in regulation of mood and emotions: the limbic- 
thalamic-cortical circuit, which includes part of the 
thalamus, the medial and ventrolateral prefrontal cortex, and 
the limbic-striatal-pallidal-thalamis cortical circuits, which 
include the striatum, the ventral pallidum, and the regions of 
the former circuit (Soares and Mann, 1997). The cerebellum 
is part of these networks projecting to several structures of 
the brainstem and limbic system, such as the amygdala, 
hypothalamus, hippocampus, and septum. Thus, we 
identified critical areas, part of the brain networks devoted 
to mood and motor control, which had structural alterations 
from the very early phase of the disorder. These 
abnormalities in the brain circuits may be the expression of 
a biological vulnerability, or the precocious signs of the 
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disorder. Hence, it is plausible to believe that these areas 
play an early role in the mechanism of BD. Taken together, 
our findings add an important piece to the complex puzzle 
of the mechanism of BD. In fact, in contrast with other 
severe psychiatric disorders, in particular schizophrenia, 
where a possible pathogenesis related to 
neurodevelopmental disruption is supported by classical 
neurodevelopmental models (Fatemi and Folsom, 2009; 
Lewis and Murray, 1987; Weinberger, 1987), it is still 
uncertain whether neurodevelopment is implicated in the 
physiopathology of BD. It is possible that environmental 
factors, especially early traumatic factors, may interplay 
with a specific genetic susceptibility, affecting the clinical 
characteristics of the disorder (Janiri et al., 2015) as well as 
altering the development of specific brain areas and leading 
to inadequate mood regulation (Etain et al., 2008). In fact, 
while other authors suggested that the decrease of GM 
volumes may be a neurodegenerative effect due to the 
course of the disease (Frey et al., 2008), we found that the 
structural alterations did not change over the course of the 
disorders. This strengthens the idea that they may be a 
signature of the disorder, if not real endophenotypes of BD. 
Finally, in a preliminary analysis, as already stated, we 
compared patients with BD-I and BD-II to determine 
whether to consider them as one singular group or two 
separate groups. Notably, we found that their age-related 
GM and WM trajectories were indistinguishable. Beyond 
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the clinical phenomenology, there is still a dearth of 
neurobiological data on the difference between BD-I and 
BD-II, and findings from pathophysiological and 
neuroimaging studies are still not consistent (Vieta and 
Suppes, 2008). Our findings do not support the current 
division between the two types of BD based on the presence 
of mania or hypomania, at least according to the brain 
structural data here considered. 
 
 
2.5 Limitations 
 
 
Before concluding, we should mention several issues 
potentially limiting the generalizability of our results. Our 
findings suggest a neurodevelopmental pathogenesis for 
BD. We know that each brain structure has its own 
developmental trajectory (Giedd et al., 1999) and that 
illness may affect it. Patients with BD and HC showed 
differences in both GM and WM structures already at the 
age of 21 years, i.e., the lowest age we could recruit. We 
cannot know how such differences developed before that 
age, but we know that they started at an earlier age. 
Alterations could have been present at any time before that 
age and may even have started before the onset of the 
illness. Another consideration is that all our patients were on 
medication, often on polypharmacy, as usually happens in 
the pharmacological treatment of patients with severe illness 
61 
 
(Centorrino et al., 2005). To identify age-related changes, it 
would be desirable to follow up patients over time using 
longitudinal study designs. However, this would be 
unethical in untreated patients. To overcome this hurdle, it  
is possible to draw some conclusions about changes 
occurring with time by comparing different age ranges in a 
sample of adult patients with BD. However, the 
neurobiology of late-onset BD in drug-naïve patients may 
differ from that of the most common, early-onset BD 
(Oostervink et al., 2015). Longitudinal studies may 
investigate better than cross-sectional studies any change 
with time, with each patient representing his/her own 
control. How-ever, this would entail a considerable 
economic effort and would carry the risk of increased 
patient/control drop-out, thus necessitating the inclusion of a 
higher number of subjects to avoid the study being 
underpowered. This is why studies with more than 10 years 
of follow-up in BD are lacking. In spite of the intrinsic 
limitations of cross-sectional designs, such designs may 
yield reliable, real-world, results if sufficiently powered. 
Furthermore, we cannot exclude a neuroprotective role of 
drug treatment that prevented increased neurodegeneration 
from occurring. Moreover, we did not find any difference in 
GM and WM age-related trajectories between patients with 
BD-I and BD-II. Given the small number of patients with 
BD-II (n=29), we cannot rule out the possibility that this 
lack of difference may have been attributable to insufficient 
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statistical power. However, that risk was minimized by the 
fact that we were focused on type II error and the 
comparisons were performed at a significance level of 
p<0.05 uncorrected for multiple comparisons. Finally, our 
clinical sample consisted of patients with BD without other 
comorbidities. Although, on the one hand, this may limit the 
generalizability of our findings, on the other hand it 
increases their reliability. 
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CHAPTER 3 
 
 
 
Study 2: Association between Duration of Lithium 
Exposure and Hippocampus/Amygdala Volumes in Type 
I Bipolar Disorder 
 
 
 
 
3.1 Introduction 
 
 
Limbic and subcortical structures are involved in 
emotional generation, expression, experience,  and 
regulation (Phan et al., 2002) and are structurally and 
functionally altered in individuals with mood disorders (i.e., 
bipolar disorder [BD], major depressive disorder [MDD]) 
and psychotic disorders (Phan et al., 2002). A growing body 
of histological (Gigante et al., 2011; Hercher et al., 2009) 
and magnetic resonance imaging (MRI) (Graham et al., 
2013; Janiri et al., 2017; Phillips and Swartz, 2014) findings 
suggest that the amygdala and hippocampus, in particular, 
are structurally altered among persons with BD. However, 
MRI studies of these structures in BD are discrepant with 
respect to the direction and magnitude of such alterations, 
with larger (Altshuler et al., 1998; van Erp et al., 2012; 
Hallahan et al., 2011) smaller (Almeida et al., 2009; 
Bearden et al., 2008; Haller et al., 2011; Ong et al., 2012; 
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Rimol et al., 2010; Wijeratne et al., 2013) or unaltered 
(Arnone et al., 2009; Kempton et al., 2011; McDonald et 
al., 2004) hippocampal and amygdalar volumes reported 
when persons with BD are compared to healthy controls 
(HC). 
Some authors hypothesized that these inconsistencies 
are due to the effect of psychotrophic medications, some of 
which may alter the volumes of some brain structures 
(Hafeman et al., 2012; Hajek et al., 2012b). Pre-clinical 
(McDonald et al., 2015; Quiroz et al., 2010) and clinical 
studies suggest that treatment with lithium–an agent that has 
been used for more than 70 years in the treatment of BD 
(A.H., 2006) – alters brain structure, especially limbic and 
subcortical structures (Bearden et al., 2008; Foland et al., 
2008; Germaná et al., 2010; Hajek, Cullis, et al., 2012a; 
Hibar et al., 2016; Radenbach et al., 2010; Savitz et al., 
2010; Usher et al., 2010). Indeed, hippocampal and 
amygdalar volumes are larger in lithium-treated patients 
than non-treated patients (Foland et al., 2008; Germaná et 
al., 2010), and the volumes of these structures are larger 
(Usher et al., 2010) or unchanged (Bearden et al., 2008; 
Hajek, Cullis, et al., 2012a) in lithium-exposed patients 
when compared to HC. These observations prompted 
hypotheses regarding potential neuroprotective effects of 
lithium (Hajek, Kopecek, et al., 2012), but inconsistencies 
in the observed effects of lithium on the direction and 
magnitude of lithium-related changes in limbic and 
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subcortical structures (using MRI-based techniques) has not 
yielded scientific consensus on this matter (Chepenik et al., 
2009; Doty et al., 2008; Kempton et al., 2009; Rimol et al., 
2010). 
One possible explanation for these inconsistencies is 
that failure of most studies to consider possible time- 
dependent effects of lithium on the volumes of brain 
structures. Preclinical evidence suggests that the short-and 
long-term effects of lithium on neurons differ (Dixon and 
Hokin, 1998). Consistent with preclinical findings, MRI- 
based volumetric studies in humans are mixed with respect 
to the short-term effects of lithium on hippocampal volumes 
(Monkul et al., 2007; A. Simonetti et al., 2016; Yucel et al., 
2008) but relatively consistent with respect to the 
association between long-term lithium intake and larger 
hippocampal volumes in BD (Hajek, Kopecek, et al., 2012; 
A. Simonetti et al., 2016). The majority of studies that 
focused on the amygdala in BD have not evaluated the 
effects of duration of lithium exposure (Doty et al., 2008; 
Foland-Ross et al., 2012; Rimol et al., 2010; Savitz et al., 
2010), but there is within these studies a suggestion of an 
association between long-term lithium treatment and larger 
amygdalar volumes (Germaná et al., 2010; Hartberg et al., 
2015; Selek et al., 2013). The effect of lithium on 
subcortical volumes is not well established and findings 
reported to-date are conflicting with respect to influence of 
lithium-treatment duration  on thalamic, pallidal, putaminal, 
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and nucleus accumbens volumes (Abramovic et al., 2016; 
López-Jaramillo et al., 2017) or no effects (Brambilla et al., 
2001; Ong et al., 2012; Quigley et al., 2015). 
Accordingly, the aim of this study was to investigate 
the effects of lithium-treatment duration on the volumes of 
limbic and subcortical structures by comparing four groups: 
BD type I (BD-I) naïve to lithium treatment, BD-I with 
short-term lithium treatment, BD-I with long-term lithium 
treatment, and HC. Based on the extant literature on limbic 
and subcortical volumes in BD-I - with the illness being 
associated with smaller limbic structure volumes and 
lithium treatment associated with larger volumes of these 
structures - the present study tested the hypothesis that long- 
term lithium treatment was associated with larger limbic and 
subcortical volumes when compared to short-term or no 
lithium treatment. Moreover, it was hypothesized that  
limbic and subcortical volumes would not differ between 
long-term lithium-treated patients and HC. 
 
 
3.2 Methods and Materials 
 
 
The study was approved by the Santa Lucia  
Foundation Ethics Committee and undertaken in accordance 
with the guidelines of the Helsinki Declaration of 1975. All 
participants gave their written informed consent to 
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participate in the research after they had received a complete 
explanation of the study procedures. 
To be sure about the group representability, a power 
analysis was performed using G*Power statistical software 
(Erdfelder et al., 2009). Results revealed that a total sample 
size of at least 27 subjects would have greater than 80% 
power to detect a difference between groups, with an alpha 
value of <0.05 (two tailed). 
 
Participants 
 
 
Seventy individuals with a diagnosis BD-I according to 
the DSM-IV-TR criteria (American Psychiatric Association, 
2000) were recruited from the Sant’Andrea outpatient 
lithium clinic and the ambulatory of neuropsychiatry of the 
IRCCS Santa Lucia Foundation in Rome, Italy, and 
subsequently assessed at the Laboratory of Neuropsychiatry 
of the Santa Lucia Foundation in Rome, Italy. 
Inclusion criteria were: 1) a diagnosis of BD-I; 2) age 
between 18 and 65 years; 3) at least five years of education; 
and 4) suitability for MRI scanning. Exclusion criteria were: 
1) lifetime substance dependence or history of substance 
abuse in the one-year period before the assessment; 2) any 
(for HC) or additional (for patients) Axis I or Axis II 
disorders; 3) any neurological disorders; 4) suspicious of 
dementia or cognitive impairment based on a Mini-Mental 
State Examination (MMSE) (Folstein et al., 1975b) score 
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lower than 25, consistent with normative data in the Italian 
population (Measso et al., 1993), or a diagnosis of dementia 
according to DSM-IV-TR (American Psychiatric 
Association, 2000) criteria confirmed by a clinical 
neuropsychological evaluation using the Mental 
Deterioration Battery (Carlesimo et al., 1996); 5) major 
medical illnesses, e.g., diabetes, obstructive pulmonary 
disease or asthma, hematological and oncological disorders, 
pernicious anemia, significant gastrointestinal, renal, 
hepatic, endocrine, or cardiovascular system diseases, newly 
treated hypothyroidism; and 6) any potential brain 
abnormality or microvascular lesion as apparent on 
conventional FLAIR images. In particular, we imputed the 
presence, severity and location of vascular lesions according 
to the semi-automated method published by our group (Iorio 
et al., 2013). 
Initial BD-I diagnoses of potential participants were 
made by their treating psychiatrists, who provided the 
investigators with all available clinical information on the 
potential participants’ past and current medical histories. A 
senior study psychiatrist then performed confirmatory 
diagnostic using the DSM-IV-TR Axis I disorders (SCID-I) 
(First et al., 2002) and the Structured Clinical Interview for 
DSM-IV Axis II personality disorders (SCID-II) (First et 
al., 1997). When diagnostic disagreement occurred between 
the treating and study psychiatrists, additional information 
needed to establish a consensus was obtained. When 
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diagnostic disagreement persisted despite such efforts, the 
participant was excluded from the sample. 
From the initial sample, 25 patients were excluded due 
to the above-mentioned exclusion criteria. The remaining 45 
patients were further divided in three groups according with 
the duration of lithium exposure: 15 patients with a lithium 
exposure of 24 or more months (long-exposure group [LE]), 
15 patients with a lithium exposure of less than 24 months 
(short-exposure group [SE]), and 15 patients naïve to 
treatment with lithium (no-exposure group [NE]). Forty- 
seven out of sixty (78%) subjects of this sample were 
previously enrolled in another study that assessed the effect 
of lithium on the hippocampal subfields (A. Simonetti et al., 
2016). These participants were here selected with the 
purpose of creating three groups without differences in 
either clinical variables (i.e. duration of illness, number of 
episodes, current mood state) and/or past and current 
exposure to pharmacotherapies (i.e. antipsychotics, 
antidepressants, benzodiazepines, mood stabilizers other 
than lithium). 
Twenty-four months was chosen as a cut-point for 
dividing duration of lithium treatment into short-and long- 
term categories based on our prior study of the association 
between duration of lithium exposure on hippocampal 
subfield volumes in patients with BD-I (A. Simonetti et al., 
2016). This categorization of duration of lithium treatment 
also is consistent with those in prior reports demonstrating 
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alterations in limbic cortical volumes associated with 
longer-term lithium exposure (van Erp et al., 2012; Hajek, 
Cullis, et al., 2012; Yucel et al., 2007). 
In the BD-I groups of the present study, depressive and 
manic symptoms were evaluated using the 17-item 
Hamilton Depression Rating Scale (HAM-D) (Hamilton, 
1960) and the Young Mania Rating Scale (YMRS) (Young 
et al., 1978), respectively. For the  lithium-treated 
subgroups, the hypothesized effects of lithium treatment 
required an assumption of continuous exposure. Assessment 
of lithium exposure was made by review of clinical data 
provided by each participant’s treating psychiatrist(s)and 
general practitioner(s). 
Fifteen HC were assessed using the SCID-I (First et 
al., 2002a) (First et al., 2002a) and SCID-II (First et al., 
1997) in order to exclude any Axis I or Axis II disorder or 
any major mental disorders in their first-degree relatives. 
The study exclusion criteria for patient groups were also 
applied to potential HC participants. 
 
Image acquisition and processing 
 
 
Each participant underwent whole-brain T1-weighted 
imaging using a 3T Allegra™ MR system (Siemens, 
Erlangen, Germany) with a standard quadrature head coil. 
Whole-brain T1-weighted images were obtained in the 
sagittal plane using a modified driven equilibrium Fourier 
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transform (MDEFT) sequence (TE/TR = 2.4/7.92 ms, flip 
angle 15o, voxel-size 1 × 1 × 1 mm3) (Deichmann et al., 
2004). 
Limbic and subcortical volumes were determined using 
the automated procedure for volumetric measures of brain 
structures implemented in FreeSurfer 5.1 
(https://surfer.nmr.mgh.harvard.edu) installed on a CentOS 
Linux 6.4. The automated procedure of subcortical volume 
segmentation has been described previously (Fischl et al., 
2002). Intracranial volume (ICV), that includes biological 
material such as meninges and cerebrospinal fluid in 
addiction to brain tissue, was calculated to correct the 
regional brain volumes analyses (Buckner et al., 2004). 
Specifically, we corrected the volume of each subcortical 
structure for ICV according to the proportion method 
(Sanfilipo et al., 2004). 
 
Statistical analyses 
 
 
The four study groups were compared for socio- 
demographic and clinical characteristics. Chi-Square test 
was used for nominal variables (i.e. gender, current mood 
state and past and current pharmacotherapy), while one-way 
analysis of variance (ANOVA) was applied for continuous 
variables (i.e., age, years of education, duration of illness, 
number of episodes, lithium exposure, YMRS and HAM-D 
scores). 
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Tests for differences in volumes of limbic (i.e. 
amygdala, hippocampus) and subcortical (i.e., caudate, 
hippocampus, nucleus accumbens, pallidum, putamen, 
thalamus) structures between the four study groups were 
performed using ANOVA, with diagnosis as independent 
variable and subcortical volumes as dependent variables. 
The Fischer’s PLSD test was used for pairwise post-hoc 
comparisons for volumes that were found significantly 
different among groups. An alpha level of < 0.05 was used 
for comparative tests of significance, to which Bonferroni 
adjustment for multiple comparisons was then applied (p< 
(0.05/14) = 0.0036). 
 
3.3 Results 
 
 
Sociodemographic and clinical characteristics 
 
 
The four study groups did not differ with respect to 
age, sex, and educational level. Furthermore, the three BD-I 
groups (NE, SE, LE) did not differ in terms of duration of 
illness, number of past episodes, current mood state, HAM- 
D scores, YMRS scores, or - with the exception of lithium 
exposure - current and past pharmacotherapies. 
 
Limbic and subcortical gray matter structure volumes 
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One-way ANOVAs demonstrated an overall effect of 
duration of lithium treatment by group on bilateral 
amygdalar and bilateral hippocampal volumes as well as on 
the right nucleus accumbens (see table 2). The bilateral 
effect of lithium treatment on amygdalar and hippocampal 
volumes survived Bonferroni correction for multiple 
comparisons but the effect on the right nucleus accumbens 
did not. There were no between-group effects of duration of 
lithium treatment on caudate, putamen, pallidum thalamus 
and left accumbens volumes. 
Post-hoc comparisons were performed to test for 
hypothesized specific between-group differences revealed 
significantly larger bilateral amygdalar and hippocampal 
volumes among both LE and HC when compared to NE. 
Amygdalar volumes were larger bilaterally in SE when 
compared to NE but did not differ from LE and HC. 
Hippocampal volumes were smaller bilaterally in SE when 
compared to LE and HC but did not differ from NE. Post- 
hoc comparisons did not yield differences in amygdalar or 
hippocampal volumes between LE and HC. 
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3.4 Discussion 
 
 
The present study demonstrates that the effect of 
lithium treatment on limbic and subcortical volumes among 
persons with BD-I varies by duration of lithium exposure. 
NE BD-I had smaller bilateral hippocampal and amygdalar 
volumes than individuals without BD-I (i.e., HC). The 
volumes of these structures did not differ between persons 
with LE BD-I and either individuals without BD-I or 
individuals with BD-I who were lithium-treatment naïve. 
Although limbic and subcortical volumes among 
individuals with BD-I who received long-term lithium 
treatment did not differ from HC, those with BD-I who 
received short-term lithium treatment demonstrated greater 
amygdalar volumes than those with BD-I who were lithium- 
treatment naïve. Individuals with BD-I who received short- 
term lithium treatment also demonstrated smaller bilateral 
hippocampal volumes than those with BD-I and either long- 
term lithium treatment patients or those without BD-I, and 
no differences from those with BD-I who were lithium- 
treatment naïve. These findings may reflect opposite effects 
of illness burden and lithium on the hippocampus and the 
amygdala. 
Hippocampus and amygdala are part of two large scale, 
selective distributed neural networks involved in the 
emotion generation, expression, experience and control 
(Mega et al., 1997). The amygdala is the subcortical focus 
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of a ventral limbic-paralimbic-subcortical-caudal network 
involved in emotional generation and expression (i.e., 
motor, endocrine, autonomic and visceral reactions to 
internal and external stimuli) while the hippocampus is a 
critical node in a dorsal limbic-paralimbic-neocortical 
network involved in subjective emotional experience, 
emotional regulation, and cognitive associations with 
emotion (Arciniegas et al., 2013). 
The pathophysiology of mood disorders mainly 
involves alterations in the cerebral networks’ structure 
and/or function as well as their interactions (Arciniegas et 
al., 2013; Phillips et al., 2003). Consistent with this view of 
the pathophysiology of mood disorders, alterations in the 
structure and/or function of the hippocampus and amygdala 
are often described in associations with bipolar disorder 
(Phillips and Swartz, 2014). Post-mortem (Benes et al., 
1998; Bowley et al., 2002) and clinical studies (Hajek, 
Cullis, et al., 2012; Hartberg et al., 2015) demonstrate lower 
numbers of neurons and smaller gray matter volumes among 
individuals with bipolar disorder who are lithium-treatment 
naïve. 
Accordingly, the observation of essentially normal 
limbic volumes among persons with LE BD-I in the present 
study suggests a possible neuroprotective or 
neurorestorative effect of lithium against illness-related 
alterations in these structure (Germaná et al.,  2010; 
Hartberg et al., 2015; Johnson et al., 2009; Selek et al., 
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2013; Wood et al., 2004). The present findings also suggest 
that this putative neuroprotective or neurorestorative effect 
also may be conferred by short-term lithium treatment but 
that this effect, in this context, is limited to the amygdala. 
Treatment with lithium exerts an acute effect on amygdalar 
activation (Strakowski et al., 2016) and is associated with 
preservation of amygdalar volumes (Selek et al., 2013). 
These short-term effects of lithium on the amygdala may 
contribute to its acute mood stabilizing properties, which 
usually begin within a few weeks of treatment initiation 
(Malhi et al., 2013). These acute effects are sustained 
overtime (Hartberg et al., 2015; Usher et al., 2010) and 
thereby protect the amygdala from damage induced by 
multiple mood episodes reflected in the smaller amygdalar 
volumes of patients with BD-I who are lithium-treatment 
naïve. 
The present findings suggest that long-term treatment 
with lithium may have a beneficial effect on hippocampal 
volumes in BD-I, consistent with the beneficial effects of 
long-term (Yucel et al., 2007), but not short-term (Kropf 
and Muller-Oerlinghausen, 1979), lithium treatment on 
memory. Indeed, short-term lithium treatment is associated 
with impairment in free recall memory (ibidem) whereas 
long-term lithium treatment improves recollection memory 
performances, in association with increased hippocampal 
volumes (Yucel et al., 2007). 
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The mechanism by which lithium exerts its possible 
neuroprotective and/or neurorestorative effect(s) and the 
differential mechanisms that inform short versus long-term 
neuroprotective effects (or their absence) remain 
incompletely defined. Short-term lithium monotherapy is 
not associated with increased hippocampal levels of N- 
acetyl-aspartate (NAA), an indirect marker of 
neuroprotection (Zanetti et al., 2015), whereas preserved 
levels of hippocampal NAA were found in patients with 
more than ten years of constant lithium assumption (Colla et 
al., 2009). Clinical studies also demonstrated that long-term 
and constant lithium assumption is associated with reduced 
risk of developing Alzheimer’s Disease (Blennow et al., 
2006), while short-or no-exposure to lithium is related to a 
higher risk (Colla et al., 2009). 
Consistent with the temporal differential of lithium 
treatment on amygdalar and hippocampal volumes observed 
in the present study, lithium-induced glutamate regulation 
occurs earlier in the amygdala than in the hippocampus 
(Gray and Mcewen, 2013; Higashitani et al., 1990; Maruta 
et al., 2005). In fact, chronic lithium administration reverses 
stress-related remodeling of dendritic arbors in both areas 
(Gray and Mcewen, 2013; Johnson et al., 2009) via the 
downregulation of glutamatergic signaling, and acute 
intraperitoneal injection of lithium reduces calcium- 
dependent NO3 levels in the amygdala, acting on the same 
mechanism (Wood et al., 2004). By contrast, short-term 
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treatment with lithium does not efficiently modulate 
glutamate-induced increase of calcium levels in the 
hippocampus (Maruta et al., 2005). Moreover, amygdalar 
activation induces long-term modifications in the 
hippocampus during memory formation processes through 
glutamatergic signaling (Higashitani et al., 1990), and the 
dysregulation of the glutamatergic transmission (Abe, 2001; 
Ikegaya et al., 1995) induces hippocampal dysfunction 
(Roozendaal et al., 2001). 
Collectively, these observations suggest that the 
delayed action of lithium on the hippocampus may be 
mediated by its modulatory effects on glutamate signaling in 
the amygdala which, in turn, induces long-term 
modifications of hippocampal function and, ultimately, 
structure (reflected in the volume of this structure). 
 
3.5 Limitations 
 
 
The observations made in the present study and 
conclusions drawn from them are limited by  its 
retrospective and cross-sectional design. A longitudinal 
study that includes protections against rater bias (i.e. 
masking of neuroimaging analyses) is needed to confirm the 
present observations of a possible neuroanatomical selective 
and time-dependent effect of lithium on limbic and 
subcortical volumes. 
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Furthermore, a neuropsychological evaluation in those 
patients is also needed to verify if differences in 
neurobiology are accompanied by differences in cognitive 
performances. The strength of any claims regarding the 
specificity of the effects observed as associated to duration 
of lithium treatment also must be tempered by 
acknowledgement of other concurrent treatments received 
by participants in this study, including anticonvulsants or 
atypical antipsychotics, many of which appear to have 
predominantly normalizing effects on brain structure in BD 
(Hafeman et al., 2012). For this reason, chi-square tests 
were performed between BD groups and demonstrated no 
differences in the past and present pharmacological. 
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CHAPTER 4 
 
 
 
Study 3: Lithium treatment impacts nucleus accumbens 
shape in bipolar disorder 
 
 
 
4.1 Introduction 
 
 
As highlighted also in chapter three, brain changes in 
deep grey matter (DGM) structures of patients with 
diagnosis of Bipolar Disorder (BD) (Hibar et al., 2016) have 
been described previously but with some inconsistences 
(McDonald et al., 2004). As mentioned in study two, the 
sources of these heterogeneity are multifactorial and one 
much debated source of bias is the effect of mood- 
stabilizing medications, primarily lithium (the archetypal 
mood stabilizer), in terms of volumetric increase induced on 
brain structures, particulary hippocampus and amygdala 
(De-Paula et al., 2016; Manji et al., 2000; Shaltiel et al., 
2007; Simonetti et al., 2016). 
In recent years, developments in brain morphometric 
methodologies have led to different structural measures that 
can integrate data derived from volumetric analysis. Indeed, 
investigation of the three-dimensional surfaces of DGM 
structures have been shown to be more sensitive than gross 
morphometric techniques, identifying group abnormalities 
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where volumetric analysis did not (Mamah et al., 2009). 
Since shape analysis enables the uncovering of localized 
changes on the surface of brain structures, it can be a very 
specific neuroimaging technique, especially in the case of 
structures with explicit regional differentiation in functions, 
such as DGM (Herrero et al., 2002). Previous studies 
investigating DGM shape in BD reported that drug-naive 
and non-psychotic BD patients, compared with healthy 
controls (HC), show widespread shape alteration of the 
caudate (Hwang et al., 2006; Ong et al., 2012) and putamen 
(Hwang et al., 2006), both as local inward and outward 
deformations. Significant shape contraction on the ventral 
surface of the right accumbens and anterior expansion of the 
globus pallidus nuclei in non-psychotic BD patients have 
also been reported (Mamah et al., 2016). However, results 
from these studies did not consider the specific effect of 
lithium treatment. Consequently, also the relationship 
between lithium-driven DGM shape variations and clinical 
correlates of BD patients, such as the degree of depressive 
and manic symptoms, was not investigated. 
In the present work, our first aim was to analyse the 
potential effect of the duration of lithium treatment on the 
morphometric measures of DGM surface. As a secondary 
goal, we aimed at identifying the relationship between the 
severity of patients’ depressive and/or manic 
symptomatology and the degree of any localized DGM 
abnormalities. To this aim we analysed the shape of seven 
85 
 
bilateral DGM structures (i.e. Accumbens, Amygdala, 
Caudate, Hippocampus, Pallidus, Putamen, and Thalamus) 
in BD (both as a whole group and stratified according to 
lithium treatment duration) and HC samples. We 
hypothesized (i) BD patients’ DGM structures shape as 
modulated by lithium treatment duration, (ii) the DGM 
surface differences between BD and HC subjects as a 
function of lithium treatment duration and (ii) that such 
differences are associated to the severity of depressive and 
(hypo)manic patients’ symptomatology. 
 
 
4.2 Methods and Materials 
 
 
Ethical permission was obtained from the local ethic 
committee of the Santa Lucia Foundation for this cross- 
sectional case-control study. All participants provided 
written informed consent to be included in the study. An a 
priori power calculation in G*power was used to determine 
the minimum sample size. Specifically, given the lack of 
prior studies about the relationship between DGM shape 
morphometry and lithium treatment, we used data from our 
prior studies on hippocampal volumetry in BD, which show 
effect sizes of 0.85-0.99 for lithium-dependent modulatory 
effects, to inform the power calculation. To be conservative 
we used the lower estimate in a power calculation using 
G*Power statistical software (Erdfelder et al., 2009), which 
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determined that a total sample size of at least 24 subjects 
would have greater than 95% power to detect a difference 
between groups, with an alpha value of <0.05 (two tailed). 
 
 
Participants 
 
 
Eighty patients with a diagnosis of BD (48 BD type I – 
32 BD type II) according to the Diagnostic and Statistical 
Manual of Mental Disorders IV-Edition, Text Revised 
(DSM-IV-TR) (American Psychiatric Association, 2000) 
were initially assessed at the Santa Lucia Foundation in 
Rome. As for study one and two, during diagnostic process 
the clinical psychiatrist who had been treating the patients 
and knew their clinical history, and who was blind to the 
aims of the study, made the preliminary diagnosis using the 
DSM-IV-TR criteria. Then, a research psychiatrist using the 
Structured Clinical Interview for DSM-IV-TR-Patient 
Edition (SCID-I/P) (M. B. First et al., 2002) confirmed the 
clinical diagnoses. If the diagnoses made at the two different 
steps were not consistent, more data were gathered and the 
diagnostic process continued until a final diagnostic 
consensus was reached. If an agreement could not be 
reached, the patient was removed from the sample. 
Inclusion criteria for all participants were: (i) age 
between 18 and 75 years, (ii) at least five years of education, 
and (iii) suitability for magnetic resonance imaging (MRI) 
87 
 
scanning. Exclusion criteria were: (i) history of alcohol or 
drug abuse in the two years before the assessment, (ii) 
lifetime drug dependence, (iii) traumatic head injury with 
loss of consciousness, (iv) past or present major medical 
illness or neurological disorders, (v) any (for HC) or 
additional (for patients with BD) psychiatric disorder or 
mental retardation, (vi) dementia or cognitive deterioration 
according to DSM-IV-TR criteria, and Mini-Mental State 
Examination (MMSE) (Folstein et al., 1975) score <25, 
consistent with normative data in the Italian population 
(Measso et al., 1993), (vii) low quality of T1- weighted 
images (i.e. presents of severe motion or scanner-generated 
artefacts), (viii) any potential brain abnormality or 
microvascular lesion as apparent on conventional fluid 
attenuated inversion recovery (FLAIR) scans, potentially 
explaining critical phenomenology; in particular, the 
presence, severity, and location of vascular lesions were 
computed according to the semi-auto- mated method 
recently published by our group (Iorio et al., 2013). 
From the original BD group (n=80), two refused to 
undergo the MRI exam and four were excluded for the low 
quality of T1- weighted images (see exclusion criteria). The 
remaining sample of 74 patients included 45 with BD-I and 
29 with BD-II. 
We also recruited 74 healthy controls (HC) in the same 
geographical area, paired-matched with the patients for age, 
gender and educational level. All HC were screened for a 
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current or lifetime history of DSM-IV-TR Axis I and II 
disorders using the Structured Clinical Interview for DSM- 
IV-TR Axis I Disorders, Research Version, Non-patient 
Edition (SCID-I-NP) (M. B. First et al., 1997) and 
Structured Clinical Interview for DSM-IV Axis II 
Personality Disorders (SCID-II) (M. First et al., 1997); they 
were also assessed to confirm that no first-degree relative 
had a history of bipolar, mood- or schizophrenia-related 
disorders. 
 
Clinical Assessment 
 
 
All patients were under stable pharmacologic treatment 
for at least six months, usually polypharmacy, including 
treatment with lithium, antidepressants, other mood- 
stabilizing agents, and stable oral dosages of one or more 
antipsychotics (data not shown; available upon request). For 
patients treated with lithium, we also collected specific 
information about treatment duration (LiTD), reported in 
months. Age at onset was defined as ‘age at onset of first 
affective symptoms’, which were investigated in an 
interview with patients and first-degree relatives. Moreover, 
we categorized patients with LiTD higher than 50% of 
illness duration (hereafter called LiTD+, N=13), those with 
LiTD shorter than 50% of illness duration (LiTD-, N=31), 
and those not taking lithium at all (NoLi, N=30), in order to 
weight up LiTD as a function of patients’ illness duration. 
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This was done in order to obtain better homogeneity (in 
terms of drug exposure) of samples. 
The overall severity of affective depressive and 
(hypo)manic symptoms was assessed using the 17-item 
Hamilton Depression Rating Scale (HAM-D) (Hamilton, 
1960), the Beck Hopelessness Scale (BHS) (Beck, 1998) 
and the Young Mania Rating Scale (YMRS) (Young et al., 
1978). The amount of depressive symptoms were scored 
rating also the psychological and somatic components of 
depression, apart from the final account (i.e. HAM-Dtot, 
HAM-Dpsy, HAM-Dsom). 
 
 
Image acquisition e processing 
 
 
All 148 participants underwent the same imaging 
protocol, which included 3D T1-weighted, T2- weighted 
and FLAIR sequences using a 3T Achieva MR scanner 
(Philips Medical Systems, Best, The Netherlands) with a 32- 
channel receiving-only head coil. Whole-brain T1- weighted 
images were obtained using a fast-field echo sequence (echo 
time/repetition: time = 5.3/11 msec, flip angle = 9°, voxel 
size = 1×1×1 mm3). T2 and FLAIR sequences were 
acquired to screen for brain pathology. 
Segmentations of seven bilateral subcortical grey 
matter nuclei (accumbens, amygdala, caudate, hippocampus, 
globus pallidus, putamen and thalamus) were generated 
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using the FIRST algorithms included in the FMRIB 
Software Library (FSL, version 5.0.0) and are fully 
described in the Appendix (see Appendix). After the 
automated segmentation by the software, the outputs were 
manually checked and confirmed for the proper nuclei 
extraction of all the subcortical structures. FSLView toolbox 
was used for neuroimaging results visualizations 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FslView). 
In case of significant results located in the nucleus 
accumbens, we further refined their localization in terms of 
specific accumbens subregions (i.e. core and shell), by using 
the Human Brain Atlas and referring to previous evidence 
on accumbens anatomy (Baliki et al., 2013). 
 
Statistical Analyses 
 
 
Comparisons between HC and BD on 
sociodemographic (i.e. age, gender, and educational level) 
and between BD subgroups on clinical (i.e. duration of 
illness, number of episodes, time of lithium exposure, 
severity of (hypo)manic/depressive symptoms and 
pharmacological treatment) characteristics were performed 
using t-test, ANOVA or chi-square tests on StatView 
statistical software, considering p< 0.05 as statistical 
significances. 
All neuroimaging statistics were performed by vertex- 
wise shape analysis along the surface of the segmented 
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subcortical structures, using FSL Randomise tool with a 
nonparametric permutation testing (Nichols and Holmes, 
2002). We used n=5000 permutation and a Threshold-Free 
Cluster Enhancement (TFCE, --T2) to correct for multiple 
comparisons (p < 0.05, after correction for multiple 
comparisons) (Smith and Nichols, 2009). 
We preliminary checked for the presence of DGM 
morphological differences between BD-I and BD-II 
performing t-tests between patients’ subgroups. Since no 
difference was found between BD subtypes, t-test 
comparisons for the same areas were performed between 
BD and HC, considering BD patient group as a whole. 
The assessment of the effect of lithium treatment 
duration on BD DGM was investigated as follows: first, 
linear regressions were performed between each DGM 
shape measure of BD (continuous dependent variable) and 
LiTD (continuous independent variable), including the 
duration of illness as covariate of no interest. The inclusion 
of the covariate was justified by the presence of an 
association with the independent variable (r= 0.354, p= 
0.0186). Second, in case of significant linear regressions 
results, comparison between HC and BD were performed 
categorizing BD patients in groups according to LiTD. To 
this aim, ANOVA analyses were conducted for each DGM 
where significant correlations results were found, using 
shape as dependent variable and group (i.e. LiTD+, LiTD-, 
NoLi, HC groups) as four-level independent variable. In 
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case of ANOVA results surviving the p<0.05 corrected 
threshold, post-hoc t-tests were performed. 
The relationship between significant BD shape 
alterations (independent variable) and clinical symptoms 
severity (i.e. HAM-Dtot, HAM-Dpsy, HAM-Dsom, BHStot) 
(dependent variable) was assessed performing linear 
regressions. Nuclei surface areas resulted in significant 
outward or inward deformations from the ANOVA 
comparisons were used as binary region of interest (ROI 
masks) to restrict subsequent post-hoc and linear regressions 
analyses. 
 
4.3 Results 
 
 
Sociodemographic and clinical characteristics 
 
 
Sociodemographic characteristics of BD and HC 
groups as well as clinical variable of NoLi, LiTD- and 
LiTD+ are shown in Table 1. BD (total sample and sub- 
groups) and HC were not different for age, gender or 
educational level (Table 1). Apart from lithium treatment, 
the patient groups did not differ significantly in terms of 
duration of illness, number of mood episodes and 
pharmacological treatment (Table 1). 
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Shape Analysis 
 
 
Both comparisons between BD-I and BD-II patients 
and between HC and BD (considered as a single diagnostic 
group) did not show significant differences in any of the 
DGM structures. 
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When evaluating the linear relationship between LiTD 
and DGM shape in BD, we found significant correlations in 
right and left accumbens nuclei (R-Accu and L-Accu, 
respectively). As stated above, in order to qualify the 
localization of significant deformation in terms of specific 
accumbens subregions (i.e. core or shell), we both referred 
results to the standard Human Brain Atlas (available at 
http://human.brain-map.org/) and to previous evidence for 
human nucleus accumbens anatomy(Baliki et al., 2013). As 
for the latter, we employed the MNI coordinates previously 
reported(Baliki et al., 2013) who anatomically defined the 
core and the shell of the nucleus accumbens. Coordinates 
were thus used as reference to create regions of interest 
corresponding to core or shell where our results were 
superimposed on. According to y-axis coordinate(Baliki et 
al., 2013) and to boundaries obtained from Human Brain 
Atlas, our results can be selectively located on the surfaces 
of the accumbens nuclei core or shell. Specifically, we 
found positive correlations bilaterally in clusters within the 
accumbens core sub-field (statistical peaks: corrected pR- 
Accu-Core = 0.016; corrected pL-Accu-Core = 0.031) indicating that 
the longer LiTD, the more outward is the bending of the 
cluster on the core (i.e. core extroflexion). Moreover, we 
found a negative correlation between shape and LiTD in a 
cluster on the boundary of the R-Accu shell sub-field 
(statistical peak: corrected pR-Accu-Shell = 0.002), indicating 
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that LiTD is associated with inward bending in this region 
(i.e. shell introflexion) (Figure 1). 
ANOVA performed on R-Accu and L-Accu shape 
between diagnostic groups (LiTD+, LiTD-, NoLi and HC) 
showed significant bilateral results (statistical peaks: 
corrected  pL-Accu-ANOVA=0.025;   correced pR-Accu-
ANOVA=0.025) (Figure 2). Post-hoc t-tests revealed R-Accu 
shell outward deformation in the NoLi group compared  to  
LiTD+ (statistical  peak:   corrected pR-Accu-Shell = 0.016) and 
HC (statistical peak: corrected pR-Accu-Shell = 0.002). 
Moreover, the LiTD- group showed L-Accu core inward 
deformation compared to HC (statistical peak: corrected pL-
Accu-Core = 0.027). Details on results and clusters coordinates 
are shown in Table 2. 
The shape of BD L-Accu-Core was positively 
correlated with HAM-Dtot score (statistical peaks: corrected 
pL-Accu-core= =0.02), HAM-Dsom (statistical peaks: corrected pL-
Accu-core=0.005) and BHStot score (statistical peaks: corrected 
pL-Accu-core=0.03) (Table 2, Figure 3), indicating the more 
inward deformation the higher depression symptom 
severity. No significant associations were found for 
YMRStot scores. 
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Figure 1. Relationship between patients’ lithium treatment duration and nucleus 
accumbens shape morphometry. 
Linear regression results using lithium treatment duration (months) and accumbens nuclei 
shape deformations (distance from mean template, mm3) as variables of interest. a) right 
accumbens shell; b) right accumbens core and c) left accumbens core; d) Statistical maps for 
significant (TFCE-corrected) right/left accumbens core inward and right accumbens shell 
outward deformations (in red) superimposed onto representative nucleus accumbens masks 
(light blu). Borders of shell and core nuclei are drawn using solid black lines and taken from 
the Human Brain Atlas (available in http://human.brain-map.org/). 
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Figure 2. Comparison between healthy subjects and patients with bipolar disorder 
stratified according to lithium treatment duration. 
a) 3D visualization of ANOVA results: right accumbens shell outward and left 
accumbens core inward deformations (in red) superimposed onto a representative 
nucleus accumbens mask (in blue); b) Mean total deformation (distance from mean 
template, mm3) of right accumbens shell (grey) and left accumbens core (orange) in 
patients with lithium treatment duration longer/shorter then 50% of illness duration 
(respectively, BD_LiTD+, BD_LiTD-), patients never treated with lithium (BD_NoLi) 
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Figure 3. Clinical correlates of left accumbens inward deformation. Relationship between 
deformations resulted from ROI ANOVA and patients depressive/hopelessness symptom 
scores, assessed through a) Somatic subscale of Hamilton Depression Rating Scale (HAM- 
Dsom); b) Total score of Hamilton Depression Rating Scale (HAM-Dtot); c) Total score of 
Beck Hopelessness Scale (BHStot). 
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4.4 Discussion 
 
 
Effects of lithium treatment duration on DGM shape is 
relevant in BD patients and possible deformations are linked 
to the depressive and (hypo)manic phenomenology. Indeed, 
we found significant bilateral extroflexction effect 
dependent to increased duration of lithium treatment on the 
core of BD accumbens surfaces, while a concomitant 
introflection effect was found on the shell of right 
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accumbens. A further analysis between groups with 
different treatment duration, showed that NoLi e LiTD- 
groups had inward/outward deformations both on L-Accu 
core and R-Accu shell surfaces when compared to HC and 
LiTD+. L-Accu core boundary inward deformation was also 
found comparing LiTD- group and HC. We also found that 
only deformation of L-Accu-Core shape was significantly 
correlated with increased depression severity. 
To the best of our knowledge, this is the first report 
describing an association between lithium treatment 
duration and accumbens nuclei shape in BD patients. 
Previous studies investigating the impact of lithium 
treatment on brain structures, mainly focused on volume 
(Hibar et al., 2016; Alessio Simonetti et al., 2016) and 
cortical thickness (Giakoumatos et al., 2015). Results 
revealed a trophic effect of lithium treatment resulting in 
volume preservation of deep grey matter assemblies (e.g. 
hippocampus, amygdala, thalamus and basal ganglia) and 
cortical thickening in frontal, parietal and occipital regions 
as well as in the precuneus and precentral areas (Abramovic 
et al., 2016; A. Simonetti et al., 2016). This was also 
confirmed by post-mortem studies demonstrating lower 
numbers of neurons among individuals with BD who are 
lithium-treatment naïve (Benes et al., 1998; Bowley et al., 
2002). As for the nucleus accumbens, animal studies found 
that lithium modulates neuronal activity and 
neurotransmission in models of the disorder. In particular, 
101 
 
chronic administration of lithium reverses many of the 
phenotypes of Clock-Δ19 mice, which display behaviours 
(i.e. increased exploratory drive in novel environments, 
significant reduction in sleep, decreased anxiety related 
behaviours, and increase in cocaine preference) that are very 
similar to those found in the manic phase of human BD. 
Interestingly, Clock-Δ19 mice have higher dopamine levels 
in the nucleus accumbens and chronic lithium treatment 
decreases dopamine tissue levels in their nucleus accumbens 
(Coque et al., 2011). Along this line of evidence, it has been 
shown that chronic lithium treatment regiment inhibits 
dopamine neurotransmission in the nucleus accumbens (Can 
et al., 2016). However, acute lithium treatment did not elicit 
the same reduction in dopamine amplitude following 60 Hz 
pulse train stimulation in the ventral tegmental area, 
suggesting that long-term lithium administration ameliorates 
mania phenotypes by stabilizing the readily releasable 
dopamine pool in ventral tegmental area axon terminals in 
the nucleus accumbens. However, direct evidence of 
potential effects of lithium treatment duration on nucleus 
accumbens morphometry in humans is still lacking. 
The nucleus accumbens is connected to the limbic and 
extrapyramidal motor systems and, having dopamine as a 
principal neurotransmitter, has a central role in the cerebral 
reward system. Acting as a limbic-motor interface, it 
regulates motivation and emotional processes and is 
involved in the mechanisms of a number of the most 
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disabling neuropsychiatric disorders (Mavridis et al., 2011). 
Moreover, together with the cingulate cortex, the nucleus 
accumbens is a component of the anatomically defined basal 
ganglia–thalamocortical circuit (Alexander et al., 1990; 
Devinsky et al., 1995), that is considered to be a key 
element of the functional organization of the limbic system, 
and is often implicated in mood regulation (Groenewegen et 
al., 1996). Owing in part to its neuroanatomical 
connectivity, the nucleus accumbens has been proposed to 
integrate mnemonic and emotional signals within the limbic 
system, linking nodes in the frontal and temporal lobes and 
determining the response priorities of an organism. Thus, 
the nucleus accumbens is thought to integrate these signals 
and turn them into action, via output to pallidal and other 
subcortical motor effector sites through which signal 
outflow from this region may bias the direction and  
intensity of behaviour. Recently, Has been proposed a more 
accurate way for characterizing its functions, overcoming 
the pedantic view that the nucleus accumbens merely acts as 
a reward centre relay (Floresco, 2015). Specifically, the 
nucleus accumbens is involved in modulation of cerebral 
processing of motivationally relevant goals by promoting 
likelihood, efficiency, and vigour of behaviours intended to 
obtain those goals, driving exploration of novel stimuli and 
procurement of things worth having (rewards) or the 
avoidance of aversive consequences. Moreover, the core and 
shell areas modulate different functions in this motivational 
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process: the core has a more prominent role in instigating 
approach behaviour toward motivationally relevant stimuli 
(“go to it” function) while the shell drives behaviour to stay 
on tasks until the rich of a goal (“stay to it” function), 
suppressing irrelevant or non-rewarded actions. 
Evidence for reward and dopamine neural systems 
alterations in mood disorders like mania, major depression 
and BD have been widely reported both in humans and 
animal models (Abler et al., 2008; Naranjo et al., 2001; 
Nestler and Carlezon, 2006; Satterthwaite et al., 2015). 
Furthermore, it has been proposed a “dopamine 
dysregulation syndrome” model for the BD pathophysiology 
(Berk et al., 2007), where a cyclical dysregulation in 
quantitative dopaminergic transmission is the main 
construct. Even if our work does not directly asses this 
aspect related to dopamine release, our results support this 
model, showing a complex pattern of lithium-dependent 
surface modulatory effects on such central node for 
dopamine and rewarding systems. 
The second important result of the present study is the 
association between left accumbens core inward 
deformation and both hopelessness and depressive symptom 
severity in areas of the core. Our results of the increased left 
core inward deformation associated with higher symptom 
severity support the hypothesis of a decreasing “go to it” 
brain signalling as pathophysiological correlate of 
depressive phenomenology in BD. Amotivational/anhedonic 
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features are crucial components of depression and, 
interestingly, the left lateralized finding of nucleus 
accumbens core deformation in BD may be explained by the 
crucial role of the dominant hemisphere in motivational 
behaviours (Pizzagalli et al., 2005). Studies conducted over 
several decades support the use of long-term lithium 
treatment to prevent depression relapse in patients with 
bipolar disorder (Geddes et al., 2004). In this context, our 
findings may reflect one of the neurobiological mechanisms 
underpinning the therapeutic effect of lithium, as part of its 
efficacy on preventing depression may unfold through a 
long-term remodeling of cortical-subcortical connections 
related to the motivational/hedonic dimension. 
 
 
4.5 Limitations 
 
 
Several issues have to be considered before 
concluding. First, the sample size of LiTD+ group is 
relatively small. However, it is adequate to detect shape 
differences because of the moderate to large effect size we 
observed. Second, our results should be replicated also with 
a longitudinal approach for definitively demonstrating a 
causal effect between lithium exposure and accumbens 
nuclei neuroprotection. Third, our patients were treated also 
with different psychotrophic drugs that might potentially 
affect accumbens nuclei shape. However, the BD subgroups 
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showed no differences in terms of non-lithium 
pharmacological drugs, making unlikely the probability that 
they may have influenced our results. 
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CHAPTER 5 
 
 
Conclusions 
 
 
Results from study 1, despite the above-mentioned 
limitations, are important for several reasons. Using a model 
based on cross-sectional case–control comparisons at 
different ages, the study demonstrated that the volumes of 
several brain areas are reduced from the very beginning of 
the illness course of BD, and that neurodegenerative 
features are not present. Moreover, we found that the brain 
areas showing volume reduction (the posterior cingulate 
cortex, cerebellum, thalamus, and posterior limb of the 
internal capsule) are strictly involved in mood and motor 
control processes. Since these reductions are present from 
the very beginning of the illness course, a role for these 
brain areas in the mechanism of BD is hypothesized. Lastly, 
our findings do not support the current distinction between 
the two types of BD based on the presence of mania or 
hypomania and suggest that patients with BD may belong to 
a unitary illness type, at least according to the data obtained 
here. 
In study two, results about the effect of lithium 
exposure on limbic and subcortical gray matter volumes in 
BD-I appears to be time-dependent and relatively specific to 
the hippocampus and the amygdala, with short-term effects 
on the amygdala and long-term effects on both structures. 
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Finally, study 3 results are the first to demonstrate that 
duration of lithium treatment affects nucleus accumbens 
surface morphology in BD. Indeed, DGM morphometry in 
BD patients never treated with lithium compared to LiTD+ 
and HC group result in subtle shape abnormalities on 
bilateral accumbens nuclei surfaces, that is L-Accu core 
inward and R-Accu shell outward deformations. Coherently, 
we found that LiTD exerts a double significant 
morphometry effect, that is the core extroflextion and the 
shell introflextion, as the time of treatment increases. 
Morphometric features of L-Accu core surface deformation 
in BD group showed significant correlations with the 
severity of depressive phenomenology, being the less 
inward deformation associated to the lower depressions 
symptoms, especially in terms of somatic and components. 
Taken together our results suggest that the duration of 
lithium treatment could act modulating and counteracting 
the BD accumbens microstructural baseline conditions as 
part of the mechanism of action in its mood stabilizing 
effects. 
Results from studies 2 and 3 give strength to the 
clinical importance of long-term lithium treatment in BD-I. 
However, longitudinal prospective studies are necessary to 
confirm that the observed findings really reflect the effects 
of duration of lithium treatment on limbic and subcortical 
volumes and shape in BD-I. 
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APPENDIX I 
 
 
Voxel-based morphometry 
 
 
Voxel-based morphometry (VBM) is an sMRI 
technique that measures brain tissue concentrations and 
makes inferences about the brain on the basis of differences 
in tissue classifications. Strictly speaking, it is a post- 
processing method of morphological images, however, I 
considered it here as it is used widely in neuropsychiatric 
research. Indeed, the technique has been reliably used in 
psychiatric research for many years (Job et al., 2003; 
Spencer et al., 2007), however it has not made a transition 
into the clinical arena. The VBM technique is heavily 
dependent on statistical and computational evaluation of 
differences in tissue classes. Indeed, it is a computationally 
and time intensive neuroimaging technique that can provide 
detailed information relating to changes in grey-white 
matter composition within the brain. The technique is based 
on a series of computational steps that correct the MR 
images for large-scale differences in gross anatomy prior to 
statistical evaluation. The computational steps include: (i) 
spatial normalization of all the images to a common 
reference space or template. The purpose of this step is to 
correct for global differences in brain shape; (ii) the 
segmentation of tissue classes into grey matter, white matter 
and cerebrospinal fluid. To assist the segmentation process, 
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the intensity of the structural images is often corrected for 
inhomogeneities caused by technical issues relating to the 
MRI head coil; and (iii) the final step involves smoothing 
the segmented grey and white matter images, which helps to 
compensate for the inexact nature of the normalization 
process. Large sample sizes are needed for identifiable 
changes to achieve statistical significance. Hence, currently 
it is not a technique that can be used to investigate changes 
in grey and white matter composition in individual patients. 
Another limitation of VBM is that it assumes the brain 
consists purely of grey matter, white matter and 
cerebrospinal fluid. This makes analysis of groups with 
pathologies such as tumor and stroke using normalization 
and segmentation procedures very difficult (Mechelli et al., 
2005). 
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Appendix II 
 
 
 
Freesurfer segmentation 
 
 
This procedure automatically segments and labels each 
anatomic structure based upon an atlas containing 
probabilistic information on the location of structures. This 
technique automatically assigns a neuroanatomical label to 
each voxel in a MRI volume based on probabilistic 
information estimated from a manually-labeled training set. 
The first stage is an affine registration with Talairach space 
followed by an initial volumetric labeling and correction 
from variation in intensity due to “intensity field bias.” 
Finally, a high dimensional non-linear volumetric alignment 
to the Talairach atlas is performed and the volume is 
labeled. The labeling uses an algorithm based on both a 
subject-independent probabilistic atlas and subject-specific 
measured values assigning a value at each point in the space 
using three types of probabilities: 1) the probability of a 
given point to belong to each of the label classes; 2) the 
probability that a given point belongs to a label classes 
given its neighboring points; and 3) the probability 
distribution function (for volume-based labeling is measured 
by the intensity at that voxel) of the measured value is 
estimated separately for each class at each point (Fischl et 
al., 2002, 2004). This method provides advantages similar 
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to manual region-of-interest (ROI) drawing (Jovicich et al., 
2009; Morey et al., 2009), without the risk of biases, 
offering an anatomically accurate rendering of regional 
volumes (Fischl et al., 2002). 
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APPENDIX III 
 
 
Shape Analysis 
 
Segmentations of seven bilateral subcortical grey 
matter nuclei (accumbens, amygdala, caudate, hippocampus, 
globus pallidus, putamen and thalamus) were generated 
using the FIRST algorithms included in the FMRIB 
Software Library (FSL, version 5.0.0). FIRST is a fully 
automated model-based segmentation/registration software, 
providing analyzing tools both for volume estimations and 
localized differences in shape 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST). 
The segmentation process is based on the shape and 
appearance models, constructed from 336 manually 
segmented images using Gaussian assumptions combined 
with a Bayesian probabilistic approach (Patenaude et al., 
2011). Specifically, FIRST algorithms ascertain the most 
probable shape by means of linear combinations of shape 
variations employing the learned manually segmented 
models. Moreover, the segmentation process includes 
boundary correction and registration to a MNI152 template 
using 12 degrees of freedom as well as a subcortical mask to 
detect and eliminate voxels outside the subcortical structure. 
Shape was then expressed as a mean with modes of 
variation (principal components) (ibidem). 
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After the automated segmentation by the software, the 
outputs need to be manually checked and confirmed for the 
proper nuclei extraction of all the subcortical structures. 
